ZyVersa Therapeutics (ZVSA) 10-K 25 Mar 24 2023 FY Annual report Financial data

Cover

Cover - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Mar. 21, 2024	Jun. 30, 2023
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2023
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--12-31
Entity File Number	001-41184
Entity Registrant Name	ZYVERSA THERAPEUTICS, INC.
Entity Central Index Key	0001859007
Entity Tax Identification Number	86-2685744
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	2200 N. Commerce Parkway
Entity Address, Address Line Two	Suite 208
Entity Address, City or Town	Weston
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33326
City Area Code	(754)
Local Phone Number	231-1688
Title of 12(b) Security	Common Stock, $0.0001 par value per share
Trading Symbol	ZVSA
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Entity Shell Company	false
Entity Public Float				$ 5.6
Entity Common Stock, Shares Outstanding			7,594,863
Documents Incorporated by Reference [Text Block]	None
ICFR Auditor Attestation Flag	false
Document Financial Statement Error Correction [Flag]	false
Auditor Firm ID	688	42
Auditor Name	Marcum LLP	Ernst & Young LLP
Auditor Location	New York, NY	Orlando, Florida

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current Assets:
Cash	$ 3,137,674	$ 5,902,199
Prepaid expenses and other current assets	215,459	225,347
Vendor deposits		235,000
Total Current Assets	3,353,133	6,362,546
Equipment, net	6,933	17,333
In-process research and development	18,647,903	100,086,329
Goodwill		11,895,033
Security deposit	98,476	46,659
Operating lease right-of-use asset	7,839	98,371
Total Assets	22,114,284	118,506,271
Current Liabilities:
Accounts payable	8,431,583	6,025,645
Accrued expenses and other current liabilities	1,754,533	2,053,559
Operating lease liability	8,656	108,756
Total Current Liabilities	10,194,772	8,187,960
Deferred tax liability	844,914	10,323,983
Total Liabilities	11,039,686	18,511,943
Commitments and contingencies (Note 8)
Redeemable common stock, subject to possible redemption, 0 and 1,880 shares outstanding as of December 31, 2023 and 2022, respectively		331,331
Stockholders’ Equity:
Preferred stock, value	1	1
Common stock, $0.0001 par value, 250,000,000 shares authorized; 4,052,119 and 257,604 shares issued at December 31, 2023 and 2022, respectively, and 4,052,057 and 257,604 shares outstanding as of December 31, 2023 and 2022, respectively	405	26
Additional paid-in-capital	114,300,484	104,584,147
Accumulated deficit	(103,219,124)	(4,921,178)
Treasury stock, at cost, 62 and 0 shares at December 31, 2023 and 2022, respectively	(7,168)
Total Stockholders’ Equity	11,074,598	99,662,997
Total Liabilities, Temporary Equity and Stockholders’ Equity	22,114,284	118,506,271
Series A Preferred Stock [Member]
Stockholders’ Equity:
Preferred stock, value		1
Series B Preferred Stock [Member]
Stockholders’ Equity:
Preferred stock, value	$ 1	$ 1

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2023	Dec. 31, 2022
Temporary equity, shares outstanding	0	1,880
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	1,000,000	1,000,000
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	4,052,119	257,604
Common stock, shares outstanding	4,052,057	257,604
Treasury stock shares	62	0
Series A Preferred Stock [Member]
Preferred stock, shares authorized	8,635	8,635
Preferred stock, shares issued	50	8,635
Preferred stock, shares outstanding	50	8,635
Series B Preferred Stock [Member]
Preferred stock, shares authorized	5,062	5,062
Preferred stock, shares issued	5,062	5,062
Preferred stock, shares outstanding	5,062	5,062

Consolidated Statement of Opera

Consolidated Statement of Operations - USD ($)	1 Months Ended	11 Months Ended	12 Months Ended
	Dec. 31, 2022	Dec. 12, 2022	Dec. 31, 2023
Income Statement [Abstract]
Financial Designation, Predecessor and Successor [Fixed List]	Successor	Predecessor	Successor
Operating Expenses:
Research and development	$ 399,894	$ 5,407,859	$ 3,207,573
General and administrative	420,174	7,605,205	11,213,201
Impairment of in-process research and development			81,438,426
Impairment of goodwill			11,895,033
Total Operating Expenses	820,068	13,013,064	107,754,233
Loss From Operations	(820,068)	(13,013,064)	(107,754,233)
Other (Income) Expense:
Interest (income) expense		427,542	(457)
Change in fair value of derivative liabilities		607,001
Pre-Tax Loss	(820,068)	(14,047,607)	(107,753,776)
Income tax benefit	745,050		9,455,830
Net Loss	(75,018)	(14,047,607)	(98,297,946)
Deemed dividend to preferred stockholders		(10,015,837)	(7,948,209)
Net Loss Attributable to Common Stockholders	$ (75,018)	$ (24,063,444)	$ (106,246,155)
Net Loss Per Share
Net loss per share, basic	$ (0.29)	$ (0.99)	$ (108.97)
Net loss per share, diluted	$ (0.29)	$ (0.99)	$ (108.97)
Weighted Average Number of Common Shares Outstanding
Weighted average number of shares outstanding, basic	257,604	24,194,270	975,035
Weighted average number of shares outstanding , diluted	257,604	24,194,270	975,035

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Equity (Deficiency) - USD ($)		Preferred Stock [Member] Series A Preferred Stock [Member]	Preferred Stock [Member] Series A Preferred Stock [Member] Predecessor [Member]	Preferred Stock [Member] Series B Preferred Stock [Member]	Common Stock [Member]	Common Stock [Member] Predecessor [Member]	Treasury Stock, Common [Member]	Additional Paid-in Capital [Member]	Additional Paid-in Capital [Member] Predecessor [Member]	Retained Earnings [Member]	Retained Earnings [Member] Predecessor [Member]	Total	Predecessor [Member]
Balance at Dec. 31, 2021						$ 242			$ 40,065,109		$ (52,896,817)		$ (12,831,466)
Balance, shares at Dec. 31, 2021						24,167,257
Stock-based compensation									3,524,801				3,524,801
Net loss											(14,047,607)	$ (14,047,607)	(14,047,607)
Issuance of preferred stock in private placement	[1]		$ 6						1,865,378				1,865,384
Issuance of preferred stock in private placement, shares	[1]		625,639
Conversion of convertible notes payable into preferred stock	[2]		$ 18						5,658,870				5,658,888
Conversion of convertible notes payable into preferred stock, shares	[2]		1,802,193
Conversion of preferred stock into common stock			$ (24)			$ 64			(40)
Conversion of preferred stock into common stock, shares			(2,427,832)			6,406,210
Conversion of convertible notes payable into common stock	[3]					$ 29			5,838,180				5,838,209
Conversion of convertible notes payable into common stock, shares	[3]					2,940,537
Balance at Dec. 12, 2022		$ 1	$ 0	$ 1	$ 26	$ 335		$ 104,527,814	$ 56,952,298	$ (4,846,160)	$ (66,944,424)	99,681,682	$ (9,991,791)
Balance, shares at Dec. 12, 2022		8,635		5,062	257,604	33,514,004
Stock-based compensation								56,333				56,333
Net loss										(75,018)		(75,018)
Balance at Dec. 31, 2022		$ 1		$ 1	$ 26			104,584,147		(4,921,178)		99,662,997
Balance, shares at Dec. 31, 2022		8,635		5,062	257,604
Stock-based compensation								1,192,963				1,192,963
Net loss										(98,297,946)		(98,297,946)
Reclassification of formerly redeemable common stock								331,331				331,331
Reclassification of formerly redeemable common stock, shares					1,880
Issuance of common stock pursuant to vendor agreements					$ 10			671,610				671,620
Issuance of common stock pursuant to vendor agreements, shares					104,571
Registration costs associated with preferred stock issuance								(5,500)				(5,500)
Registered offering of common stock	[4]				$ 80			15,723,828				15,723,908
Registered offering of common stock , shares	[4]				807,759
Redemption of Series A Preferred Stock		$ (1)						(10,295,048)				(10,295,049)
Redemption of Series A Preferred Stock, shares		(8,550)
Conversion of Series A Preferred Stock into common stock
Conversion of series A preferred stock into common stock , shares		(35)			500
Shares issued as consideration for extension of lock-up period					$ 9			1,156,769				1,156,778
Shares issued as consideration for extension of lock-up period, shares					86,976
Treasury stock acquired, at cost							$ (7,168)					(7,168)
Treasury stock acquired, at cost, shares							(62)
Warrant modification								181,891				181,891
Exercise of pre-funded warrants					$ 256			870				1,126
Exercise of pre-funded warrants, shares					2,555,565
Warrant inducement offer - exercise proceeds	[5]				$ 20			757,627				757,647
Warrant inducement offer - exercise proceeds, shares	[5]				203,463
Round up share adjustment due to reverse split					$ 4			(4)
Round up share adjustment due to reverse split, shares					33,801
Balance at Dec. 31, 2023				$ 1	$ 405		$ (7,168)	$ 114,300,484		$ (103,219,124)		$ 11,074,598
Balance, shares at Dec. 31, 2023		50		5,062	4,052,119		(62)
[1]Includes gross proceeds of $ 1,964,524 99,140 5,230,000 428,888 3,961,000 709,608 1,167,601 18,114,193 2,390,285 966,349 208,702

Consolidated Statements of Ch_2

Consolidated Statements of Changes in Stockholders' Equity (Deficiency) (Parenthetical) - Predecessor [Member] - USD ($)	11 Months Ended	12 Months Ended
	Dec. 12, 2022	Dec. 31, 2023
Gross proceeds	$ 1,964,524	$ 18,114,193
Issuance costs	99,140	2,390,285
Convertible Notes Payable [Member]
Principal amount	5,230,000
Accrued interest	428,888
Convertible Notes Payable One [Member]
Principal amount	3,961,000
Accrued interest	709,608
Derivative liability	$ 1,167,601
Warrant [Member]
Gross proceeds		966,349
Issuance costs		$ 208,702

Consolidated Statement of CashF

Consolidated Statement of CashFlows - USD ($)	1 Months Ended	11 Months Ended	12 Months Ended
	Dec. 31, 2022	Dec. 12, 2022	Dec. 31, 2023
Statement of Cash Flows [Abstract]
Financial Designation, Predecessor and Successor [Fixed List]	Successor	Predecessor	Successor
Cash Flows From Operating Activities:
Net loss	$ (75,018)	$ (14,047,607)	$ (98,297,946)
Adjustments to reconcile net loss to net cash used in operating activities:
Impairment of in-process research and development			81,438,426
Impairment of goodwill			11,895,033
Stock-based compensation	56,333	3,524,801	1,192,963
Issuance of common stock pursuant to vendor agreements			671,620
Shares issued as consideration for extension of lock-up period			1,156,778
Amortization of debt discount		39,492
Change in fair value of derivative liability		607,001
Depreciation of fixed assets	532	9,868	10,400
Non-cash rent expense	4,443	79,918	90,532
Deferred tax benefit	(745,050)		(9,479,069)
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	36,606	73,675	56,547
Vendor deposits	125,645	255,627	136,524
Accounts payable	(2,076,863)	6,617,064	2,405,938
Operating lease liability	(4,786)	(86,100)	(100,100)
Accrued expenses and other current liabilities	(715,730)	1,431,620	101,535
Net Cash Used In Operating Activities	(3,393,888)	(1,494,641)	(8,720,819)
Cash Flows From Financing Activities:
Proceeds from issuance of common stock in public offering			18,114,193
Registration and issuance costs associated with common stock issuance			(2,417,095)
Redemption of Series A Preferred Stock			(10,695,611)
Proceeds from issuance of preferred stock in private placement		1,964,524
Purchase of treasury stock			(7,168)
Exercise of pre-funded warrants			1,126
Warrant inducement offer - exercise proceeds			966,349
Registration and issuance costs associated with preferred stock issuance		(99,140)	(5,500)
Net Cash Provided By Financing Activities		1,865,384	5,956,294
Net (Decrease) Increase in Cash	(3,393,888)	370,743	(2,764,525)
Cash - Beginning of Year	699,324	328,581	5,902,199
Cash - End of Year	5,902,199	699,324	3,137,674
Supplemental Disclosures of Cash Flow Information:
Conversion of convertible notes payable and accrued interest into preferred stock		5,658,888
Conversion of convertible notes payable and accrued interest into common stock		5,838,209
Reclassification of formerly redeemable common stock			331,331
Recognition of ROU asset and lease liability upon adoption of ASC 842		182,732
Accounts payable for deferred offering costs	240,691	667,224	44,892
Warrant modification - incremental value			181,891
Warrant inducement offer - incremental value			$ 134,591

Business Organization, Nature o

Business Organization, Nature of Operations and Risks and Uncertainties	12 Months Ended
	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business Organization, Nature of Operations and Risks and Uncertainties	Note 1 – Business Organization, Nature of Operations and Risks and Uncertainties Organization and Operations Larkspur Health Acquisition Corp. (“Larkspur”), a blank-check special purpose acquisition company, was incorporated in Delaware on March 17, 2021. On December 12, 2022, Larkspur consummated the Business Combination (see Note 4 – Business Combination for additional details) with ZyVersa Therapeutics, Inc. (“Predecessor”) which was incorporated in the State of Florida on March 11, 2014 as Variant Pharmaceuticals, Inc. On the date of consummation of the Business Combination, Larkspur (“New Parent”) changed its name to ZyVersa Therapeutics, Inc. and the Predecessor changed its name to ZyVersa Therapeutics Operating, Inc. (the “Operating Company”) after merging with a subsidiary of the New Parent, with the Operating Company being the surviving entity, which resulted in it being incorporated in Delaware and it being a wholly-owned subsidiary of the New Parent (collectively the “Successor”). References to the “Company” or “ZyVersa” refer to the Successor for the Successor period from December 13, 2022 to December 31, 2022 and to the Predecessor for the Predecessor period from January 1, 2022 to December 12, 2022. ZyVersa is a clinical stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. Our mission is to develop drugs that optimize health outcomes and improve patients’ quality of life. Risks and Uncertainties On March 10, 2023, Silicon Valley Bank (“SVB”) was closed by the California Department of Financial Protection and Innovation, and the Federal Deposit Insurance Corporation (“FDIC”) was appointed as receiver. Similarly, on March 12, 2023, Signature Bank and Silvergate Capital Corp. were each swept into receivership. A statement by the Department of the Treasury, the Federal Reserve and the FDIC stated that all depositors of SVB would have access to all of their money after only one business day of closure, including funds held in uninsured deposit accounts. The standard deposit insurance amount is up to $ 250,000

Going Concern and Management_s

Going Concern and Management’s Plans	12 Months Ended
	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern and Management’s Plans	Note 2 – Going Concern and Management’s Plans The Company has incurred losses each year since its inception and has a net working capital deficiency as of December 31, 2023. Subsequent to December 31, 2023, the Company received proceeds of $ 2.7 The Company has not yet achieved profitability and expects to continue to incur cash outflows from operations. It is expected that its research and development and general and administrative expenses will continue to increase and, as a result, the Company will eventually need to generate significant product revenues to achieve profitability. The Company’s cash flow needs include the planned costs to operate its business, including amounts required to fund research and development, working capital, and capital expenditures. The Company’s future capital requirements and the adequacy of its available funds will depend on many factors, including the Company’s ability to successfully commercialize its products and services, competing technological and market developments, and the need to enter into collaborations with other companies or acquire other companies or technologies to enhance or complement our product and service offerings. We intend to raise additional capital in the future to fund operations. If the Company is unable to secure additional capital, it may be required to curtail its research and development initiatives and take additional measures to reduce costs in order to conserve its cash. The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”), which contemplate continuation of the Company as a going concern and the realization of assets and satisfaction of liabilities in the normal course of business. The financial statements do not include any adjustment that might become necessary should the Company be unable to continue as a going concern.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2023
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 3 – Summary of Significant Accounting Policies Basis of Presentation and Principles of Consolidation The accompanying consolidated financial statements have been derived from the accounting records of the Company and its consolidated subsidiaries. As a result of the Business Combination, for accounting purposes, Larkspur Health Acquisition Corp. was the acquirer and ZyVersa Therapeutics, Inc. was the acquiree and accounting predecessor. Therefore, the financial statement presentation includes the financial statements of the Predecessor for the periods prior to December 13, 2022 and the Successor for the periods including and after December 13, 2022, including the consolidation of ZyVersa Therapeutics Operating, Inc. All significant intercompany balances have been eliminated in the consolidated financial statements. The consolidated financial statements have been prepared in accordance with United States Generally Accepted Accounting Principles (“U.S. GAAP”) and pursuant to the accounting rules and regulations of the United States Securities and Exchange Commission (“SEC”). ZYVERSA THERAPEUTICS, INC. NOTES TO FINANCIAL STATEMENTS On December 4, 2023, the Company effected a reverse stock split of its common stock at a ratio of 1-for-35 (the “Reverse Split”). Upon the effectiveness of the Reverse Split, every 35 issued shares of common stock were reclassified and combined into one share of common stock. Use of Estimates Preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the financial statements and the amounts disclosed in the related notes to the financial statements. The Company bases its estimates and judgments on historical experience and on various other assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Company’s balance sheets and the amounts of expenses reported for each of the periods presented are affected by estimates and assumptions, which are used for, but not limited to, fair value calculations for equity securities, derivative liabilities, goodwill impairment, in-process research and development, share based compensation and acquired intangible assets, as well as establishment of valuation allowances for deferred tax assets. Certain of the Company’s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that actual results could differ from those estimates. Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents in the financial statements. As of December 31, 2023 and 2022, the Company had no cash equivalents. The Company has cash deposits which, at times, may be in excess of Federal Deposit Insurance Corporation (“FDIC”) insurance limits. The Company has not experienced losses in such accounts and periodically evaluates the creditworthiness of its financial institutions. See Note 1 – Risks and Uncertainties. Business Combination In applying the acquisition method of accounting for business combinations, amounts assigned to identifiable assets and liabilities acquired were based on estimated fair values as of the date of acquisition, with the remainder recorded as goodwill. Intangible assets are initially valued at fair value using generally accepted valuation methods appropriate for the type of intangible asset. In-process research and development (IPR&D) acquired in a business combination is capitalized as an indefinite-lived intangible asset until regulatory approval is obtained, at which time it is accounted for as a definite-lived asset and amortized over its estimated useful life, or discontinuation, at which point the intangible asset will be written off. Long-Lived Assets and Goodwill The Company accounts for long-lived assets in accordance with the provisions of ASC 360-10-35, Property, Plant and Equipment, Impairment or Disposal of Long-lived Assets The Company accounts for goodwill and intangible assets in accordance with ASC 350, Intangibles – Goodwill and Other In determining whether a quantitative assessment is required, the Company will evaluate relevant events or circumstances to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If, after performing the qualitative assessment, an entity concludes that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, the entity would perform the quantitative impairment test described in ASC 350. However, if, after applying the qualitative assessment, the entity concludes that it is not more than likely that the fair value is less than the carrying amount, the quantitative impairment test is not required. The Company bases these assumptions on its historical data and experience, industry projections, micro and macro general economic condition projections, and its expectations. Equipment, Net Equipment is stated at cost, net of accumulated depreciation, which is recorded commencing at the in-service date using the straight- line method at rates sufficient to charge the cost of depreciable assets to operations over their estimated useful lives, which is 5 52,000 45,067 34,667 Successor 10,400 Successor 532 Predecessor 9,868 ZYVERSA THERAPEUTICS, INC. NOTES TO FINANCIAL STATEMENTS Financing Costs Debt issuance costs, which primarily consist of direct, incremental professional fees incurred in connection with a debt financing, are reported as a direct deduction from the face amount of the notes payable and are amortized over the contractual term of the underlying notes payable using the effective interest method. Convertible Promissory Notes The Company evaluates its convertible instruments to determine if those contracts or embedded components of those contracts qualify as derivative financial instruments to be separately accounted for in accordance with Topic 815 “Derivatives and Hedging” (“ASC 815”) of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”). The accounting treatment of derivative financial instruments requires that the Company record any bifurcated embedded features at their fair values as of the inception date of the agreement and at fair value as of each subsequent balance sheet date. Any change in fair value is recorded in earnings each period as non-operating, non-cash income or expense. The Company reassesses the classification of its derivative instruments at each balance sheet date. If the classification changes as a result of events during the period, the contract is reclassified as of the date of the event that caused the reclassification. Bifurcated embedded features are recorded at their initial fair values which create additional debt discount to the host instrument. Fair Value of Financial Instruments The Company measures the fair value of financial assets and liabilities based on ASC 820 “Fair Value Measurements and Disclosures” (“ASC 820”), which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value: Level 1 — quoted prices in active markets for identical assets or liabilities; Level 2 — quoted prices for similar assets and liabilities in active markets or inputs that are observable; and Level 3 — inputs that are unobservable (for example, cash flow modeling inputs based on assumptions). The carrying amounts of the Company’s financial instruments, such as cash, accounts payable, accrued expenses, and deposits approximate fair values due to the short-term nature of these instruments. Income Taxes The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of items that have been included or excluded in the financial statements or tax returns. Deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (“temporary differences”) at enacted tax rates in effect for the years in which the temporary differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the assets will not be realized. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the statements of operations in the period that includes the enactment date. The Company utilizes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Leases See Note 3 - Summary of Significant Accounting Policies – Recently Adopted Accounting Pronouncements for further details on the adoption of ASC 842. Research and Development Research and development expenses are charged to operations as incurred. Stock-Based Compensation The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. The fair value of the award is measured on the grant date. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. ZYVERSA THERAPEUTICS, INC. NOTES TO FINANCIAL STATEMENTS Fair Value of Stock Options and Warrants The Company has computed the fair value of stock options and warrants granted using the Black-Scholes option pricing model. Option forfeitures are accounted for at the time of occurrence. Successor common stock is being valued using the market approach using the trading prices of the common stock on the Nasdaq Capital Market. During 2022, the fair value of the Predecessor common stock was determined using a market approach based on the status of the business combination agreement arm’s length discussions with the acquirer at each valuation date and which agreement was ultimately entered into on July 20, 2022 with a Predecessor valuation of $ 85 Net Loss Per Common Share Basic net loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding during the period, plus the weighted average number of pre-funded warrants outstanding where common stock is issuable for little or no consideration. Diluted net income per common share is computed by dividing net income by the weighted average number of common and dilutive common-equivalent shares outstanding during each period. The following table sets forth the outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to do so would be anti-dilutive: Schedule of Anti-dilutive Securities Excluded From Calculation of Diluted Net Loss Per Share FinancialDesignationPredecessorAndSuccessorFixedList 2023 2022 December 12, 2022 Financial Designation, Predecessor and Successor [Fixed List] Successor Successor Predecessor Successor Predecessor December 31, 2023 2022 December 12, 2022 Predecessor warrants [1] - - 8,560,561 Successor warrants [1] 9,032,739 246,534 [2] - Predecessor options - - 10,039,348 Successor options 101,752 56,950 - Successor Series A Convertible Preferred Stock 714 24,671 [3] - Successor Series B Convertible Preferred Stock 20,664 14,465 [4] - Predecessor Series A Convertible Preferred Stock - - 6,406,210 Total potentially dilutive shares 9,155,869 342,620 25,006,119 [1] As part of the InflamaCORE, LLC license agreement, warrants to purchase 3,404 [2] Does not include an additional 98,686 [3] Does not include an additional 98,686 [4] Does not include an additional 6,199 Segment Reporting The Company operates and manages its business as one reportable and operating segment. All assets and operations are in the U.S. The Company’s Chief Executive Officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance. Recently Adopted Accounting Pronouncements In December 2019, the FASB issued ASU 2019-12, “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes,” which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. ASU 2019-12 is effective for fiscal years beginning after December 15, 2021. This standard was adopted on January 1, 2022 and did not have a material impact on the Company’s consolidated financial statements. ZYVERSA THERAPEUTICS, INC. NOTES TO FINANCIAL STATEMENTS In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. This new standard provides clarification and reduces diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (such as warrants) that remain equity classified after modification or exchange. This standard is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Companies should apply the new standard prospectively to modifications or exchanges occurring after the effective date of the new standard. This standard was adopted on January 1, 2022 and did not have a material impact on the Company’s consolidated financial statements. In February 2016, the FASB issued Accounting Standards Update (“ASU”) 2016-02, “Leases (Topic 842).” ASU 2016-02 requires that a lessee recognize the assets and liabilities that arise from operating leases. A lessee should recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term. For leases with a term of 12 months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and lease liabilities. In transition, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. This amendment will be effective for private companies and emerging growth companies for fiscal years beginning after December 15, 2021, and interim periods within fiscal years beginning after December 15, 2022. The FASB issued ASU No. 2018-10 “Codification Improvements to Topic 842, Leases” and ASU No. 2018-11 “Leases (Topic 842) Targeted Improvements” in July 2018, and ASU No. 2018-20 “Leases (Topic 842) - Narrow Scope Improvements for Lessors” in December 2018. ASU 2018-10 and ASU 2018-20 provide certain amendments that affect narrow aspects of the guidance issued in ASU 2016-02. ASU 2018-11 allows all entities adopting ASU 2016-02 to choose an additional (and optional) transition method of adoption, under which an entity initially applies the new leases standard at the adoption date and recognizes a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. The Company adopted ASU 2016-02 on December 31, 2022, effective January 1, 2022 and the adoption of this ASU resulted in the recording of right-of-use assets and lease liabilities for the Company’s operating leases in the approximate amounts of $ 182,732 199,642 16,910

Business Combination

Business Combination	12 Months Ended
	Dec. 31, 2023
Business Combination and Asset Acquisition [Abstract]
Business Combination	Note 4 – Business Combination On July 20, 2022, the Operating Company entered into a Business Combination Agreement, (the “Business Combination Agreement”), with Larkspur, Larkspur Merger Sub Inc. (“Merger Sub” a wholly owned subsidiary of Larkspur) and Stephen Glover, in his capacity as the representative of the shareholders of the Operating Company. Larkspur was a blank-check special purpose acquisition company (“SPAC”) that became a public company as a result of completing its initial public offering on December 23, 2021 and it was formed for the purpose of effecting a combination with a private company business that could benefit by gaining access to the capital that can be raised because its shares are publicly traded on Nasdaq. On December 12, 2022, the Business Combination was consummated following a special meeting of stockholders on December 8, 2022, where the stockholders of Larkspur, considered and approved, among other matters, a proposal to adopt the Business Combination Agreement. Further information regarding the Business Combination is set forth in (i) the proxy statement / prospectus included in the registration statement on Form S-4 (File No. 333-266838), as amended and supplemented, originally filed with the SEC on August 12, 2022 and declared effective by the SEC on November 14, 2022; and (ii) the Current Report on Form 8-K filed with the SEC on July 22, 2022. The Business Combination included the following transactions: ● The Operating Company merged into Merger Sub with the result that the Operating Company was the surviving entity and incorporated in Delaware. ● The Operating Company’s common stockholders exchanged their 33,845,335 33,514,004 331,331 191,992 Successor 176.28 ● The 10,039,348 56,950 176.28 ● The 8,560,561 48,561 176.28 Given the non-recurring nature of Larkspur’s activities as a SPAC, pro forma financial data combining the pre-Business Combination results of both Larkspur and the Operating Company would not be meaningful and have not been presented. The Company accounted for the Business Combination as a forward acquisition of the Operating Company as it was determined that the Operating Company was a variable interest entity as of the date of the Business Combination. The New Parent is the primary beneficiary as its ownership provides the power to direct the activities of the Operating Company and the obligation to absorb the losses and/or receive the benefits of the Operating Company. ZYVERSA THERAPEUTICS, INC. NOTES TO FINANCIAL STATEMENTS Purchase Price Allocation The Business Combination was recorded using the acquisition method of accounting and the initial purchase price allocation was based on the Company’s preliminary assessment of the fair value of the purchase consideration and the fair value of the Operating Company’s tangible and intangible assets acquired and liabilities assumed at the date of acquisition. As of December 31, 2022, the purchase price allocation was not complete due to the proximity of the acquisition date to the calendar year end. As of June 30, 2023, the preliminary estimates of the acquisition-date fair value of the purchase consideration and the preliminary estimates of the purchase price allocation were confirmed, do not require measurement period adjustments, and are now considered final. The acquisition-date fair value of the elements of the purchase consideration were estimated using a market approach with Level 1 inputs (observable inputs) in the case of the fair value of the Successor’s common stock and Level 3 inputs (unobservable inputs) in the case of the fair value attributed to the Successor warrants and options. The acquiror was obligated to replace the Operating Company’s existing warrants and options pursuant to the Business Combination Agreement. Accordingly, it was necessary to allocate the fair value of the replacement warrants and options between purchase consideration (the fair value attributable to pre-combination services) and compensation for post-combination services. The fair value of the replacement warrants and options attributable to post-combination services was $ 584,260 1,731,237 The final estimates of the acquisition-date fair value of the purchase consideration were as follows: Schedule of Fair Value of the Purchase Consideration Successor common stock $ 67,197,300 Successor warrants 12,190,015 Successor options 11,864,556 Total fair value of the purchase consideration $ 91,251,871 The final acquisition-date fair values of the assets acquired and liabilities assumed (see the table below) were determined by management, with the assistance of a third-party valuation expert specifically for the in-process research and development (“IPR&D”). The estimated fair value of the IPR&D assets were determined using the “income approach” which is a valuation technique that provides an estimate of the fair value of an asset based on market participant expectations of the cash flows an asset would generate over its remaining useful life using Level 3 inputs. Some of the more significant assumptions utilized in the valuations include the estimated net cash flows for each year for each asset, the appropriate discount rate necessary to measure the risk inherent in the future cash flows, the life cycle of each asset, the potential regulatory and commercial success risk, royalties on net sales, as well as other factors. There are inherent uncertainties related to these factors and management’s judgment in applying them to arrive at the estimated fair values. The excess of the purchase price over the estimated fair values of the identifiable net assets acquired was recorded as goodwill, which management believes is attributable to the assembled workforce and other intangible assets that don’t qualify for separate recognition. Schedule of Estimated Fair Values of Identifiable Net Assets Acquired Recorded as Goodwill Current assets, including cash of $ 699,324 $ 1,093,223 In-process research and development 100,086,329 Goodwill 11,895,033 Other non-current assets 64,523 Total assets acquired 113,139,108 Current liabilities 10,818,204 Deferred tax liabilities 11,069,033 Total assumed liabilities 21,887,237 Net assets acquired $ 91,251,871 IPR&D recorded for book purposes is considered an indefinite-lived intangible asset until the completion or the abandonment of the research and development efforts. Because the acquisition was structured as a stock sale, the IPR&D and the goodwill do not have any tax basis and will not be deductible for tax purposes. Impairment While management did not identify any unfavorable developments directly related to its IPR&D assets through December 31, 2023, management did determine that it was more likely than not that the Company’s single reporting unit’s fair value was below its carrying amount, due to a significant and sustained decline in the Company’s market capitalization through December 31, 2023. ZYVERSA THERAPEUTICS, INC. NOTES TO FINANCIAL STATEMENTS The Company’s estimated market capitalization included an estimated implied control premium of approximately 100%. The Company’s determination of a reasonable control premium that an investor would pay, over and above the market capitalization for a control position, included a number of factors: ● Market control premium; The identification of recent public market information of comparable peer acquisition transactions. The selection of comparable peer acquisition transactions is subject to judgment and uncertainty. ● Impact of low public float and limited trading activity on market capitalization: A significant portion of the Company’s common shares are owned by a concentrated number of investors. The public float of the Company’s common shares, calculated as the percentage of common shares freely traded by public investors divided by the Company’s total shares outstanding, is significantly lower than that of the Company’s publicly traded peers. Based on the Company’s evaluation of third-party market data, we believe there is an inherent discount impacting the Company’s share price due to the low public float and limited trading volume, thus impacting the Company’s market capitalization. As a result of the Company’s analysis, during the year ended December 31, 2023, the Company fully impaired its $ 11.9 81.4

Note Receivable

Note Receivable	12 Months Ended
	Dec. 31, 2023
Note Receivable
Note Receivable	Note 5 – Note Receivable On December 13, 2020, the Company and L&F Research LLC (“L&F”) entered into a promissory note agreement (“L&F Note Agreement”) whereby the Company agreed to accept a note receivable in the principal amount of $ 351,579 1.17 L&F is required to immediately prepay the L&F Note and all accrued and unpaid interest on the L&F Note with the following: (a) 100% of the proceeds of the second $ 500,000 6,000 The L&F Note was outstanding as of December 31, 2022 as the Company had not received payment from L&F of the amount due, nor had the Company made any required payments to L&F in connection with the license agreement described in Note 8 – Commitments and Contingencies, and such amount was recorded as a contra-liability against the milestone payments due to L&F in connection with the license agreement, which was included in accrued expenses and other current liabilities (see Note 6 – Accrued Expenses and other Current Liabilities). In recording the L&F Note receivable as a contra-liability, the Company considered the commercial substance, the intent of the parties and the overall contractual agreements between ZyVersa and L&F Research, which afford both parties the legal right to set-off the milestone liability owed by the Company to L&F Research with the L&F Note receivable to the Company. The Company determined that the amounts could be offset in the balance sheet because i) the amounts owed by and to the Company are determinable, ii) the Company has a legal right to set off the milestone liability owed to L&F Research by the amount of the L&F Note due to the Company, iii) the Company intends to set off the L&F Note receivable against the milestone liability, and iv) the set off right is enforceable by law. On March 29, 2023, the Company paid the $ 648,421 ZYVERSA THERAPEUTICS, INC. NOTES TO FINANCIAL STATEMENTS

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	12 Months Ended
	Dec. 31, 2023
Payables and Accruals [Abstract]
Accrued Expenses and Other Current Liabilities	Note 6 – Accrued Expenses and Other Current Liabilities As of December 31, 2023 and 2022, accrued expenses and other current liabilities consisted of the following: Schedule of Accrued Expenses and Other Current Liabilities 2023 2022 For the Years Ended December 31, 2023 2022 L&F milestone payment liability $ 500,000 $ 1,500,000 L&F Note [1] - (351,579 ) L&F, net 500,000 1,148,421 Payroll accrual 668,803 584,226 Other accrued expenses 41,969 214,229 Federal income tax payable - 106,683 Bonus accrual 536,500 - Registration delay liability [2] 7,261 - Total accrued expenses and other current liabilities $ 1,754,533 $ 2,053,559 [1] See Note 5 – “Note Receivable” and Note 8 – “Commitments and Contingencies” for details of the forgiveness of the L&F Note. [2] See Note 9 – “Stockholders’ Permanent and Temporary Equity – Effectiveness Failure” for details of the registration delay liability.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2023
Income Tax Disclosure [Abstract]
Income Taxes	Note 7 – Income Taxes The Company is subject to United States federal and state income taxes. The provision for income taxes consists of the following (benefits) provisions: Schedule of Provision For Income Taxes 2023 2022 2022 Financial Designation, Predecessor and Successor [Fixed List] Successor Successor Predecessor Successor Predecessor For the Period For the Period For the Year December 13 January 1 Ended Through Through December 31, December 31, December 12, 2023 2022 2022 Current tax benefit: Federal $ - $ - $ - State 23,240 - - Current tax benefit 23,240 - - Deferred tax benefit: Federal (19,104,800 ) (151,625 ) (2,191,344 ) State (4,468,170 ) (34,844 ) (482,283 ) Deferred tax benefit (23,572,970 ) (186,469 ) (2,673,627 ) Change in valuation allowance 14,093,900 (558,581 ) 2,673,627 Provision for income taxes $ (9,455,830 ) $ (745,050 ) $ - ZYVERSA THERAPEUTICS, INC. NOTES TO FINANCIAL STATEMENTS The provision for income taxes differs from the Federal statutory rate as follows: Schedule of Provision For Income Taxes Differs From The Federal Statutory Rate 2023 2022 2022 Financial Designation, Predecessor and Successor [Fixed List] Successor Successor Predecessor Successor Predecessor For the Period For the Period For the Year December 13 January 1 Ended Through Through December 31, December 31, December 12, 2023 2022 2022 Federal statutory rate 21.0 % 21.0 % 21.0 % State tax rate, net of federal benefit 3.8 % 3.6 % 3.6 % Permanent items (2.8 )% (1.9 %) (5.4 )% Nondeductible basis difference 0.0 % 0.0 % 0.0 % Effect of change in state rate (0.1 )% 0.0 % (0.1 )% Prior period adjustments and other 0.0 % 0.0 % (0.1 )% Change in valuation allowance (13.1 )% 68.1 % (19.0 )% Effective income tax rate 8.8 % 90.8 % 0.0 % Deferred tax assets and liabilities consist of the following: Schedule of Deferred Tax Assets and Liabilities 2023 2022 December 12, 2022 Successor Successor Predecessor Successor Predecessor December 31, 2023 2022 December 12, 2022 Net operating loss carryforwards $ 9,974,075 $ 6,671,907 $ 6,639,882 Stock-based compensation expense 3,258,463 2,936,945 4,084,595 Capitalized research and development costs 2,182,104 2,421,390 2,362,939 Capitalized start-up costs 1,033,504 1,121,802 565,530 Capitalized licensing costs 647,489 687,926 689,820 Capitalized patents 351,721 288,123 273,682 Warrants 134,341 133,203 238,768 Accrued payroll 299,487 71,830 - Contributions carryforward 2,857 2,833 2,833 Operating lease liability 2,151 26,794 - Deferred tax assets 17,886,192 14,362,753 14,858,049 Valuation allowance (14,093,900 ) - (14,853,648 ) Deferred tax assets 3,792,292 14,362,753 4,401 Operating lease right-of-use asset (1,948 ) (24,236 ) - In-process research and development (4,633,535 ) (24,658,231 ) - Fixed assets (1,723 ) (4,270 ) (4,401 ) Deferred tax liabilities (4,637,206 ) (24,686,737 ) (4,401 ) Deferred tax assets, net $ (844,914 ) $ (10,323,984 ) $ - On December 31, 2023 and 2022, the Successor 40,807,990 27,515,427 32,322,138 20,567,703 27,385,445 20,458,902 The Company has assessed the likelihood that deferred tax assets will be realized and considers all available positive and negative evidence, including the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax planning strategies. A valuation allowance is established when it is “more likely than not” that all, or a portion of, deferred tax assets will not be realized. After the performance of such a review as of December 12, 2022, management believed that uncertainty existed with respect to future realization of the Predecessor deferred tax assets and therefore, established a full valuation allowance as of that date. Thus, the Predecessor recorded an increase in the valuation allowance of $ 2,673,627 ZYVERSA THERAPEUTICS, INC. NOTES TO FINANCIAL STATEMENTS As a result of the December 12, 2022 Business Combination and the availability of new deferred tax liabilities (a) the Predecessor released its $ 14,853,648 Successor 558,581 However, due to the impairment of the IPR&D and the corresponding reduction in the related deferred tax liabilities during the year ended December 31, 2023, the Company established a $ 14,093,900 Management has evaluated and concluded that there were no material uncertain tax positions requiring recognition in the Company’s financial statements as of December 31, 2023 and 2022. The Company does not expect any significant changes in its unrecognized tax benefits within twelve months of the reporting date. No tax audits were commenced or were in process during the years ended December 31, 2023 and 2022 and no tax related interest or penalties were incurred during those years. The Company’s tax returns beginning with the year ended December 31, 2020 remain subject to examination.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 8 – Commitments and Contingencies Litigations, Claims and Assessments In the normal course of business, the Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of business. The Company records contingent liabilities resulting from such claims, if any, when a loss is assessed to be probable and the amount of the loss is reasonably estimable. License Agreements L&F Research LLC The Company entered into a License Agreement with L&F Research LLC (“L&F Research”) effective December 15, 2015, as amended (the “L&F License Agreement”) pursuant to which L&F granted the Company an exclusive royalty-bearing, worldwide, sublicensable license under the patent and intellectual property rights and know-how specific to and for the development and commercialization of VAR 200, for the treatment, inhibition or prevention of kidney disease in humans and symptoms thereof, including focal segmental glomerulosclerosis. The term of the license agreement shall commence on the effective date and, unless earlier terminated in accordance with the terms of the agreement, continue until the expiration of the last-to-expire of all royalty payment obligations of licensee. The license agreement contains an up-front cash payment of $ 200,000 21.5 1,500,000 500,000 2,500,000 5 10 878,947 1.00 766,384 five years 351,579 306,411 175,789 153,324 351,578 On January 9, 2020, an amendment was entered into for the license agreement that provided for the following amendments: (i) partially extended the timing of payment of $ 1,000,000 500,000 500,000 351,579 On March 7, 2022, August 26, 2022 and December 23, 2022, the Company and L&F executed a Waiver Agreement that waives L&F’s right to terminate the license agreement or any other remedies, for non-payment of the $ 1,500,000 ZYVERSA THERAPEUTICS, INC. NOTES TO FINANCIAL STATEMENTS On February 28, 2023, the Company and L&F executed an Amendment and Restatement Agreement that waived L&F’s right to terminate the L&F License Agreement or any other remedies, for non-payment of the First Milestone Payment, until (a) March 31, 2023 as to $1,000,000 of such milestone payments (“Waiver A”) and (b) January 31, 2024 as to $500,000 of milestone payments (“Waiver B”). 351,579 648,421 March 31, 2023 500,000 January 31, 2024 30,000,000 On March 29, 2023, the Company paid the $ 648,421 On January 30, 2024, the Company paid $ 500,000 InflamaCORE On April 18, 2019, the Company entered into a license agreement with InflamaCORE, LLC (“InflamaCORE”) whereby InflamaCORE agreed to grant the Predecessor an exclusive license to the InflamaCORE Program Technology for the development and commercialization of IC 100, for the treatment of inflammation. The term of the license agreement shall commence on the effective date and, unless earlier terminated in accordance with the terms of the agreement, continue until the expiration of the last-to-expire of all royalty payment obligations of licensee. In conjunction with this license agreement, InflamaCORE entered into an agreement with the University of Miami to aggregate all of the intellectual property and technology developed by InflamaCORE scientists, who are all employees of the University of Miami, under the InflamaCORE umbrella. The term of the agreement shall commence on the effective date and shall remain in effect until the later of (a) the date on which all issued patents and filed patent applications within the patent rights have expired or been abandoned and no royalties are due or (b) twenty (20) years, unless earlier terminated in accordance with the terms of the agreement. The two agreements were executed with the understanding that ZyVersa will further develop the intellectual property and technology under the license agreement. In consideration for the license, the Predecessor agreed to pay an up-front fee to InflamaCORE in the amount of $ 346,321 22,500,000 the first milestone payment of $200,000 is triggered by the submission of an investigational new drug application for the first indication of a therapeutic licensed product). ZyVersa is required to pay sales royalties to InflamaCORE between 5% and 10%, which expire upon the latest of: (a) expiration of the last-to-expire of a patent or (b) expiration of regulatory exclusivity, as defined in the agreement. ZyVersa is required to pay sales royalties to the University of Miami between 3% and 6%. 1,000,000 400,000 2,270 815,822 2.30 405.30 600,000 200,000 460,000 Operating Leases On January 18, 2019, the Predecessor entered into a lease agreement for approximately 3,500 89,000 497,000 112,064 The Successor 154,841 Successor Predecessor 7,795 148,881 See Note 3 – Summary of Significant Accounting Policies – Recently Adopted Accounting Pronouncements for information related to the Company’s adoption of the new lease accounting standard and the recognition of a right-of-use asset and operating lease liability. ZYVERSA THERAPEUTICS, INC. NOTES TO FINANCIAL STATEMENTS A summary of the Company’s right-of-use assets and liabilities is as follows: Schedule of Right of Use Assets and Liabilities Financial Designation, Predecessor and Successor [Fixed List] Successor Successor Predecessor Successor Predecessor For the Period For the Period For the Year December 13 January 1, 2022 December 31, 2023 December 31, 2022 December 12, 2022 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows used in operating activities $ 100,099 $ 4,786 $ 86,100 Right-of-use assets obtained in exchange for lease obligations Operating leases $ - $ - $ - Weighted Average Remaining Lease Term Operating leases 0.08 1.08 1.08 Weighted Average Discount Rate Operating leases 6.5 % 6.5 % 6.5 % Future minimum payments under these operating lease agreements are as follows: Schedule of Future Minimum Payments Under Lease Amount For the year ended December 31, 2024 $ 8,703 Less: amount representing imputed interest (48 ) Total $ 8,656

Stockholders_ Permanent and Tem

Stockholders’ Permanent and Temporary Equity	12 Months Ended
	Dec. 31, 2023
Equity [Abstract]
Stockholders’ Permanent and Temporary Equity	Note 9 – Stockholders’ Permanent and Temporary Equity Authorized Capital The Predecessor was authorized to issue 75,000,000 0.00001 5,000,000 0.00001 The Successor was authorized to issue 110,000,000 0.0001 1,000,000 0.0001 Effective November 30, 2023, the Company amended its certificate of incorporation to increase the authorized number of shares of the Company’s capital stock from 111,000,000 251,000,000 110,000,000 250,000,000 Equity Incentive Plans Predecessor 2014 Equity Incentive Plan The Predecessor was authorized to issue awards under its 2014 Equity Incentive Plan (the “2014 Plan”), as amended on October 9, 2018, February 2, 2019 and February 2, 2021. Under the 2014 Plan, 102,651 The number of shares of common stock available for issuance under the 2014 Plan shall automatically increase on the first trading day of January each calendar year during the term of the 2014 Plan, beginning with calendar year 2019, by an amount equal to five percent (5%) of the total number of shares of common stock outstanding on the last trading day in December of the immediately preceding calendar year. no On December 12, 2022, in connection with the consummation of the Business Combination, the Predecessor approved the amendment to the 2014 Plan (the “2014 Plan Amendment”). The 2014 Plan Amendment provides, among other things, that upon consummation of the Business Combination, no further increases in the shares of common stock reserved and available for issuance under the 2014 Plan shall occur and no new awards shall be made under the 2014 Plan. ZYVERSA THERAPEUTICS, INC. NOTES TO FINANCIAL STATEMENTS Successor 2022 Omnibus Equity Incentive Plan The Successor is authorized to issue awards under the 2022 Omnibus Equity Incentive Plan (the “2022 Plan”). Under the 2022 Plan, 31,138 41,523 114,286 155,809 114,286 Successor Common Stock On December 12, 2022, the Company closed on the Business Combination (see Note 4 – Business Combination) which met the legal definition of a reverse merger with a publicly traded company (albeit for accounting purposes it was a forward merger). Accordingly, such Business Combination met the definition of a Qualified Offering and, as such, the $ 3,961,000 709,608 1,167,601 2,940,537 16,681 1.58835 (80% of the $1.98542 fair value per share of the Predecessor common stock which was determined using the Business Combination exchange ratio of 176.28) On June 5, 2023, the Company issued 86,976 1.2 56,507 1,156,778 During the year ended December 31, 2023, the Company entered into marketing agreements with two vendors in which the Company issued an aggregate of 104,571 671,620 Successor Equity Offerings On April 28, 2023, the Company completed an offering of 314,729 314,729 11.0 35.00 1,184,482 440,620 455,332 259,774 28,756 On July 26, 2023, the Company completed a public offering of 93,030 270,565 363,636 5.78 0.0035 2.1 0.0035 five years 5.78 523,115 125,943 236,091 87,037 26,744 47,300 ZYVERSA THERAPEUTICS, INC. NOTES TO FINANCIAL STATEMENTS On December 11, 2023, the Company completed a public offering of 400,000 3,600,000 4,000,000 4,000,000 1.25 0.0001 5.0 0.0001 five years 1.25 18 1.25 653,514 299,978 232,336 94,325 26,875 Redeemable Common Stock and Put Option On December 13, 2020 (the “Effective Date”), in connection with the L&F Note Agreement (see Note 5 – Note Receivable for details), the Predecessor and L&F entered into an agreement to provide L&F with a put option to cause the Company to purchase up to 331,331 1.00 331 On December 12, 2022, the Company closed on the Business Combination (see Note 4 – Business Combination) whereby the 331,331 1,880 176.28 On March 29, 2023, the Company forgave $ 351,579 648,421 1,880 331,331 Predecessor Series A Preferred Stock Predecessor Series A Preferred Stock Financing On March 31, 2022, the Predecessor sold 133,541 3.14 392,301 100,000 The Predecessor Series A Preferred Stock is convertible, at the option of the holder, at any time into shares of Predecessor common stock on a one-to-one basis, subject to standard antidilution adjustments. In addition, in the event of any non-exempt issuances by the Company for less than the in-force conversion price, the Predecessor Series A Preferred Stock conversion price shall be reduced on a weighted average basis. Each share of Predecessor Series A Preferred Stock shall automatically be converted into shares of Predecessor common stock at the then effective conversion price concurrently with (i) the closing of a Public Transaction or (ii) the date specified by written consent or agreement of the holders of a majority of the then outstanding shares of Predecessor Series A Preferred stock. A Public Transaction represents either (a) a firm commitment underwritten public offering; or (b) the closing of a transaction with a special purpose acquisition company (“SPAC”) listed on the Nasdaq Stock Market in which the Company would become a wholly owned subsidiary of the SPAC. The Predecessor Series A Preferred stockholders shall vote together with the Predecessor common stockholders on an as-converted basis and dividends will only be paid on an as-converted basis when, and if paid to Predecessor common stockholders. In the event of any liquidation, dissolution or winding up of the Predecessor or upon a Deemed Liquidation Event, the Predecessor Series A Preferred stockholders will be entitled to be paid, out of the assets of the Predecessor available for distribution before any payments are made to Predecessor common stockholders, one times the original purchase price, plus declared and unpaid dividends on each share of Predecessor Series A Preferred Stock or, if greater, the amount that the Predecessor Series A Preferred Stock holders would receive on an as-converted basis. The balance of any proceeds shall be distributed pro rata to the Predecessor common stockholders. Deemed Liquidation Events include (a) a merger or consolidation in which the Predecessor or a subsidiary thereof is a constituent party which results in a change-of-control (a “Merger Event”); or (b) the sale, lease, transfer, exclusive license or other disposition of all or substantially all of the assets of the Predecessor (a “Disposition Event”). ZYVERSA THERAPEUTICS, INC. NOTES TO FINANCIAL STATEMENTS The Predecessor Series A Preferred Stock is not mandatorily redeemable and therefore it is not subject to classification as a liability. The Predecessor determined that the Deemed Liquidation Events were within the control of the Predecessor and, therefore, the Predecessor Series A Preferred Stock should be classified as permanent equity. Specifically, Merger Events and Disposition Events require the approval of the board of directors pursuant to state law and the Predecessor preferred stockholders are unable to control the vote of the board of directors. The Predecessor determined that the embedded conversion options were clearly and closely related to the preferred stock host and, therefore, the embedded conversion options need not be bifurcated. However, if the conversion price is reset in connection with a subsequent issuance of securities, the Predecessor will need to assess the accounting for the price reset. Due to the Predecessor’s adoption of ASU 2020-06 on January 1, 2021, it wasn’t necessary to assess the embedded conversion options for a beneficial conversion feature. On July 8, 2022, the Predecessor sold an additional 94,393 3.14 296,400 21,200 On September 16, 2022, the Predecessor sold an additional 222,929 3.14 700,000 16,000 On December 6, 2022, the Predecessor sold an additional 174,776 3.14 548,805 2,000 Amendment of Predecessor Series A Preferred Stock Designation On May 10, 2022, the Predecessor obtained the requisite approvals to (a) amend the Predecessor Series A Preferred Stock Designation within the Predecessor’s Certificate of Incorporation to reduce the effective conversion price of the Predecessor Series A Preferred Stock from $ 3.14 2.78 3.20 331,200 Second Amendment of Predecessor Series A Preferred Stock Designation On August 31, 2022, the Predecessor filed with the Florida Department of State a second amendment to the Predecessor Series A Preferred Stock Designation within the Predecessor’s Certificate of Incorporation, which reduced the conversion price of the Predecessor Series A Preferred Stock from $ 2.78 1.19 3.20 1.37 The Predecessor determined that the reduction of the Predecessor Series A Preferred Stock conversion price, combined with the revised terms associated with the Predecessor Series A Warrants (collectively the “Second Amendment Securities”) issuable at conversion, represented a significant change requiring the application of extinguishment accounting. Accordingly, it was necessary to record the $ 9,684,637 Automatic Conversion of Predecessor Series A Preferred Stock On December 12, 2022, in connection with the Business Combination, all outstanding 2,427,832 6,406,210 6,406,210 36,340 36,340 241.50 ZYVERSA THERAPEUTICS, INC. NOTES TO FINANCIAL STATEMENTS Successor Preferred Stock Successor Series A Preferred Stock Financing In connection with the Business Combination, the Successor sold 8,635 24,671 402.50 1,000 8,635,000 The Successor Series A Preferred Stock is convertible, at the option of the holder, at any time into a number of shares of Successor common stock equal to the face value divided by the conversion price then in effect (initially $ 350.00 (a) $70.00; and (b) the lowest price of any subsequent offerings of securities at a price less than the conversion price The conversion price also resets at both 90 days and 150 days following the effectiveness of the registration of the Successor Series A Preferred Stock (each a “Commencement Date”) to the greater of (a) $70.00; and (b) 85% of the lowest of the ten consecutive daily volume-weighted average prices commencing on, and including, each Commencement Date The Successor Series A Preferred stockholders have no voting rights and dividends will only be paid on an as-converted basis when, and if paid to Successor common stockholders. In the event of any liquidation, dissolution or winding up of the Successor, each Successor Series A Preferred stockholder shall be entitled to be paid out of the assets of the Company legally available for distribution, the stated value of their holdings, plus any accrued and unpaid dividends. The balance of any proceeds shall be distributed to Successor Series A Preferred stockholders on an as-converted basis pari passu The Successor Series A Preferred Stock is not redeemable at the election of the holder and, therefore, it is classified as permanent equity. However, subject to the holder’s right to elect to convert, the Company has the right to redeem the Successor Series A Preferred Stock anytime at 120% of the face value. The Successor determined that the embedded conversion options were clearly and closely related to the preferred stock host and, therefore, the embedded conversion options need not be bifurcated. However, if the conversion price is reset in connection with a subsequent issuance of securities, the Company will need to assess the accounting for the price reset. Due to the Successor’s adoption of ASU 2020-06 on January 1, 2021, it wasn’t necessary to assess the embedded conversion options for a beneficial conversion feature. On or about April 28, 2023, cash proceeds from the April 2023 Offering in the amount of $ 10.5 8,400 10.5 3.7 6.4 On August 3, 2023, the Company entered into a redemption agreement and release with an investor which resulted in the Company, on August 4, 2023, redeeming 150 200 2,465 2.00 230,000 32,373 As a result of the April 2023 Offering, (a) the exercise price of the Series A Warrants to purchase 24,671 402.50 70.00 141,861 1.4 235 350.00 70.00 37,000 350.00 5,062 245.00 0.1 Following the triggering of the down round provision, the holders of 35 500 70.00 Successor Preferred Series B Issuance In connection with the Business Combination, the Successor issued 5,062 1,000 5,062,000 ZYVERSA THERAPEUTICS, INC. NOTES TO FINANCIAL STATEMENTS The Successor Series B Preferred Stock is convertible, at the option of the holder, at any time into a number of shares of Successor common stock equal to the face value divided by the conversion price then in effect (initially $ 350.00 The conversion price also resets at 150 days following the effectiveness of the registration of the Successor Series B Preferred Stock (each a “Commencement Date”) to the greater of (a) $ 245.00 The Successor Series B Preferred stockholders have no voting rights and dividends will only be paid on an as-converted basis when, and if paid to Successor common stockholders. In the event of any liquidation, dissolution or winding up of the Successor each Successor Series B Preferred stockholder shall be entitled to be paid out of the assets of the Company legally available for distribution, the stated value of their holdings, plus any accrued and unpaid dividends. The balance of any proceeds shall be distributed to Successor Series B Preferred stockholders on an as-converted basis pari passu The Successor Series B Preferred Stock is not redeemable and, therefore, it is classified as permanent equity. The Successor determined that the embedded conversion options were clearly and closely related to the preferred stock host and, therefore, the embedded conversion options need not be bifurcated. However, if the conversion price is reset in connection with a subsequent issuance of securities, the Successor will need to assess the accounting for the price reset. Due to the Successor’s adoption of ASU 2020-06 on January 1, 2021, it wasn’t necessary to assess the embedded conversion options for a beneficial conversion feature. Stock-Based Compensation For the year ended December 31, 2023, the Successor recorded stock-based compensation expense of $ 1,192,963 132,767 1,060,196 1,027,460 1.7 For the period December 13, 2022 through December 31, 2022, the Successor recorded stock-based compensation expense of $ 56,333 7,808 48,525 3,524,801 673,160 2,851,641 2,957,047 1.6 Stock Options On January 27, 2023, the Company granted ten 2,858 184,426 three years 73.85 On March 10, 2023, the Company granted ten 372 23,770 79.10 372 143 On May 24, 2023, the Company granted ten 41,523 555,004 499,660 three years 55,344 15.25 ZYVERSA THERAPEUTICS, INC. NOTES TO FINANCIAL STATEMENTS The grant date fair value of stock options granted during the Successor year ended December 31, 2023 and the period from December 13, 2022 through December 31, 2022 for the Successor and the period from January 1, 2022 through December 12, 2022 for the Predecessor was determined using the Black Scholes method, with the following assumptions used: Schedule of Stock Options Valuation Assumptions Successor Successor Predecessor Successor Predecessor For the Period For the Period For the Year ended December 13 January 1 December 31, 2023 December 31, 2022 December 12, 2022 Fair value of common stock on date of grant $ 15.26 78.05 n/a $ 2.27 3.00 Risk free interest rate 3.53 4.27 n/a 1.68 3.01 % Expected term (years) 5.00 6.00 n/a 3.53 6.00 Expected volatility 120 123 n/a 111 119 % Expected dividends 0.00 % n/a 0.00 % During the period ended December 12, 2022, the fair value of the Predecessor’s common stock was determined using a market approach based on the status of the business combination agreement arm’s length discussions with the acquirer at each valuation date and which agreement was ultimately entered into on July 20, 2022 with a Company valuation of $ 85 A summary of the option activity for the year ended December 31, 2023 is presented below: Schedule of Stock Option Activity Weighted Weighted Average Average Remaining Aggregate Number of Exercise Life Intrinsic Options Price In Years Value Outstanding, January 1, 2023 56,999 $ 366.29 Granted 44,753 19.52 Exercised - - Forfeited - - Outstanding, December 31, 2023 101,752 $ 220.65 6.3 $ - Exercisable, December 31, 2023 56,284 $ 333.65 5.0 $ - The following table presents information related to stock options as of December 31, 2023: Schedule of Information Related to Stock Options Options Outstanding Options Exercisable Weighted Outstanding Average Exercisable Exercise Number of Remaining Life Number of Price Options In Years Options $ 15.25 41,523 9 4,286 $ 73.85 2,858 - - $ 79.10 372 - - $ 176.05 18,952 2.1 18,952 $ 396.55 351 8.5 351 $ 405.30 20,819 5.3 20,819 $ 572.60 16,877 7.4 11,876 101,752 5.0 56,284 ZYVERSA THERAPEUTICS, INC. NOTES TO FINANCIAL STATEMENTS Stock Warrants On July 26, 2023, in connection with the July 2023 Offering (see Successor Equity Offerings above), the Company amended the exercise price of certain warrants to purchase 39,372 35.00 5.78 47,300 On August 2, August 8 and September 8, 2023, a July 2023 Offering investor exercised pre-funded warrants to purchase an aggregate of 270,565 0.0035 947 Between September 13 and September 18, 2023, the Company initiated a limited time program, which at the election of the warrant holder, would permit them to immediately exercise their July 2023 Warrants at a reduced exercise price of $ 4.75 5.5 4.75 203,463 966,400 208,702 57,980 16,131 134,591 134,591 A summary of the warrant activity for the year ended December 31, 2023 is presented below: Summary of Warrant Activity Weighted Weighted Average Average Remaining Aggregate Number of Exercise Life Intrinsic Warrants Price In Years Value Outstanding, Janaury 1, 2023 246,594 $ 376.11 Issued [4] [4] 8,881,859 2.71 Exercised [5] [5] (203,463 ) 4.75 Forfeited (9,447 ) 32.47 Repriced - Old [1] (24,672 ) 402.50 Repriced - New [1] 141,868 70.00 Repriced - Old [2] (39,372 ) 35.00 Repriced - New [2] 39,372 5.78 Repriced - Old [3] (203,463 ) 5.78 Repriced - New [3] 203,463 4.75 Outstanding, December 31, 2023 9,032,739 $ 12.34 3.2 $ - Exercisable, December 31, 2023 8,827,273 $ 12.48 3.3 $ - [1] Warrants represent the reset of the exercise price of the PIPE Warrants to purchase 24,672 70.00 [2] Warrants represent the reset of the exercise price of certain April 28, 2023 offering warrants to purchase 39,372 5.78 [3] Warrants represent the reset of the exercise price of certain July 26, 2023 offering warrants to purchase 203,463 4.75 [4] Warrants issued exclude 270,565 0.0035 3,600,000 0.0001 [5] Warrants exercised exclude 270,565 0.0035 2,285,000 0.0001 ZYVERSA THERAPEUTICS, INC. NOTES TO FINANCIAL STATEMENTS The following table presents information related to stock warrants as of December 31, 2023: Schedule of Information Related to Stock Warrants Warrants Outstanding [1] Warrants Exercisable [1] Outstanding Weighted Average Exercisable Exercise Number of Remaining Life Number of Price Warrants In Years Warrants $ 1.25 8,000,000 3.2 8,000,000 $ 4.75 203,464 n/a - $ 5.78 199,555 4.5 199,555 $ 35.00 275,378 4.3 275,378 $ 70.00 139,403 4.0 139,403 $ 176.05 2,994 1.1 998 $ 241.50 36,363 3.9 36,363 $ 402.50 173,306 4.0 173,306 $ 405.30 2,270 0.3 2,270 9,032,733 3.3 8,827,273 [1] Warrants outstanding and exercisable exclude 1,315,000 0.0001 Effectiveness Failure In connection with the Business Combination, the Company conducted the Successor Series A Preferred Stock Financing. On or about February 20, 2023, the Company failed to have the SEC declare a registration statement effective (the “Effectiveness Failure”) which covered the Successor Series A Preferred Stock registrable securities within the time period prescribed by the Securities Purchase Agreement (the “SPA”). The SPA entitles the investors to receive registration delay payments (“Registration Delay Payments”) equal to 1.5 2.0 7,261

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2023
Subsequent Events [Abstract]
Subsequent Events	Note 10 – Subsequent Events The Company has evaluated subsequent events through the date the financial statements were issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the financial statements, except as discussed below. License Agreements On January 30, 2024, the Company paid $ 500,000 Common Stock On January 2, 2024, the Company entered into a marketing agreement with a vendor in which the Company issued an aggregate of 90,000 79,200 Stock Warrants Subsequent to December 31, 2023, investors of the December 2023 Offering exercised warrants to purchase 2,138,000 1.25 2,672,500 Between January 17 and February 23, 2024, a December 2023 Offering investor exercised 1,315,000 1,314,806 0.0001 Successor 2022 Omnibus Equity Incentive Plan On January 1, 2024, the total number of shares under the Successor 2022 Omnibus Equity Incentive Plan automatically increased to 317,891

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2023
Accounting Policies [Abstract]
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The accompanying consolidated financial statements have been derived from the accounting records of the Company and its consolidated subsidiaries. As a result of the Business Combination, for accounting purposes, Larkspur Health Acquisition Corp. was the acquirer and ZyVersa Therapeutics, Inc. was the acquiree and accounting predecessor. Therefore, the financial statement presentation includes the financial statements of the Predecessor for the periods prior to December 13, 2022 and the Successor for the periods including and after December 13, 2022, including the consolidation of ZyVersa Therapeutics Operating, Inc. All significant intercompany balances have been eliminated in the consolidated financial statements. The consolidated financial statements have been prepared in accordance with United States Generally Accepted Accounting Principles (“U.S. GAAP”) and pursuant to the accounting rules and regulations of the United States Securities and Exchange Commission (“SEC”). ZYVERSA THERAPEUTICS, INC. NOTES TO FINANCIAL STATEMENTS On December 4, 2023, the Company effected a reverse stock split of its common stock at a ratio of 1-for-35 (the “Reverse Split”). Upon the effectiveness of the Reverse Split, every 35 issued shares of common stock were reclassified and combined into one share of common stock.
Use of Estimates	Use of Estimates Preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the financial statements and the amounts disclosed in the related notes to the financial statements. The Company bases its estimates and judgments on historical experience and on various other assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Company’s balance sheets and the amounts of expenses reported for each of the periods presented are affected by estimates and assumptions, which are used for, but not limited to, fair value calculations for equity securities, derivative liabilities, goodwill impairment, in-process research and development, share based compensation and acquired intangible assets, as well as establishment of valuation allowances for deferred tax assets. Certain of the Company’s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that actual results could differ from those estimates.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents in the financial statements. As of December 31, 2023 and 2022, the Company had no cash equivalents. The Company has cash deposits which, at times, may be in excess of Federal Deposit Insurance Corporation (“FDIC”) insurance limits. The Company has not experienced losses in such accounts and periodically evaluates the creditworthiness of its financial institutions. See Note 1 – Risks and Uncertainties.
Business Combination	Business Combination In applying the acquisition method of accounting for business combinations, amounts assigned to identifiable assets and liabilities acquired were based on estimated fair values as of the date of acquisition, with the remainder recorded as goodwill. Intangible assets are initially valued at fair value using generally accepted valuation methods appropriate for the type of intangible asset. In-process research and development (IPR&D) acquired in a business combination is capitalized as an indefinite-lived intangible asset until regulatory approval is obtained, at which time it is accounted for as a definite-lived asset and amortized over its estimated useful life, or discontinuation, at which point the intangible asset will be written off.
Long-Lived Assets and Goodwill	Long-Lived Assets and Goodwill The Company accounts for long-lived assets in accordance with the provisions of ASC 360-10-35, Property, Plant and Equipment, Impairment or Disposal of Long-lived Assets The Company accounts for goodwill and intangible assets in accordance with ASC 350, Intangibles – Goodwill and Other In determining whether a quantitative assessment is required, the Company will evaluate relevant events or circumstances to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If, after performing the qualitative assessment, an entity concludes that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, the entity would perform the quantitative impairment test described in ASC 350. However, if, after applying the qualitative assessment, the entity concludes that it is not more than likely that the fair value is less than the carrying amount, the quantitative impairment test is not required. The Company bases these assumptions on its historical data and experience, industry projections, micro and macro general economic condition projections, and its expectations.
Equipment, Net	Equipment, Net Equipment is stated at cost, net of accumulated depreciation, which is recorded commencing at the in-service date using the straight- line method at rates sufficient to charge the cost of depreciable assets to operations over their estimated useful lives, which is 5 52,000 45,067 34,667 Successor 10,400 Successor 532 Predecessor 9,868 ZYVERSA THERAPEUTICS, INC. NOTES TO FINANCIAL STATEMENTS
Financing Costs	Financing Costs Debt issuance costs, which primarily consist of direct, incremental professional fees incurred in connection with a debt financing, are reported as a direct deduction from the face amount of the notes payable and are amortized over the contractual term of the underlying notes payable using the effective interest method.
Convertible Promissory Notes	Convertible Promissory Notes The Company evaluates its convertible instruments to determine if those contracts or embedded components of those contracts qualify as derivative financial instruments to be separately accounted for in accordance with Topic 815 “Derivatives and Hedging” (“ASC 815”) of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”). The accounting treatment of derivative financial instruments requires that the Company record any bifurcated embedded features at their fair values as of the inception date of the agreement and at fair value as of each subsequent balance sheet date. Any change in fair value is recorded in earnings each period as non-operating, non-cash income or expense. The Company reassesses the classification of its derivative instruments at each balance sheet date. If the classification changes as a result of events during the period, the contract is reclassified as of the date of the event that caused the reclassification. Bifurcated embedded features are recorded at their initial fair values which create additional debt discount to the host instrument.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company measures the fair value of financial assets and liabilities based on ASC 820 “Fair Value Measurements and Disclosures” (“ASC 820”), which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value: Level 1 — quoted prices in active markets for identical assets or liabilities; Level 2 — quoted prices for similar assets and liabilities in active markets or inputs that are observable; and Level 3 — inputs that are unobservable (for example, cash flow modeling inputs based on assumptions). The carrying amounts of the Company’s financial instruments, such as cash, accounts payable, accrued expenses, and deposits approximate fair values due to the short-term nature of these instruments.
Income Taxes	Income Taxes The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of items that have been included or excluded in the financial statements or tax returns. Deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (“temporary differences”) at enacted tax rates in effect for the years in which the temporary differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the assets will not be realized. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the statements of operations in the period that includes the enactment date. The Company utilizes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return.
Leases	Leases See Note 3 - Summary of Significant Accounting Policies – Recently Adopted Accounting Pronouncements for further details on the adoption of ASC 842.
Research and Development	Research and Development Research and development expenses are charged to operations as incurred.
Stock-Based Compensation	Stock-Based Compensation The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. The fair value of the award is measured on the grant date. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. ZYVERSA THERAPEUTICS, INC. NOTES TO FINANCIAL STATEMENTS
Fair Value of Stock Options and Warrants	Fair Value of Stock Options and Warrants The Company has computed the fair value of stock options and warrants granted using the Black-Scholes option pricing model. Option forfeitures are accounted for at the time of occurrence. Successor common stock is being valued using the market approach using the trading prices of the common stock on the Nasdaq Capital Market. During 2022, the fair value of the Predecessor common stock was determined using a market approach based on the status of the business combination agreement arm’s length discussions with the acquirer at each valuation date and which agreement was ultimately entered into on July 20, 2022 with a Predecessor valuation of $ 85
Net Loss Per Common Share	Net Loss Per Common Share Basic net loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding during the period, plus the weighted average number of pre-funded warrants outstanding where common stock is issuable for little or no consideration. Diluted net income per common share is computed by dividing net income by the weighted average number of common and dilutive common-equivalent shares outstanding during each period. The following table sets forth the outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to do so would be anti-dilutive: Schedule of Anti-dilutive Securities Excluded From Calculation of Diluted Net Loss Per Share FinancialDesignationPredecessorAndSuccessorFixedList 2023 2022 December 12, 2022 Financial Designation, Predecessor and Successor [Fixed List] Successor Successor Predecessor Successor Predecessor December 31, 2023 2022 December 12, 2022 Predecessor warrants [1] - - 8,560,561 Successor warrants [1] 9,032,739 246,534 [2] - Predecessor options - - 10,039,348 Successor options 101,752 56,950 - Successor Series A Convertible Preferred Stock 714 24,671 [3] - Successor Series B Convertible Preferred Stock 20,664 14,465 [4] - Predecessor Series A Convertible Preferred Stock - - 6,406,210 Total potentially dilutive shares 9,155,869 342,620 25,006,119 [1] As part of the InflamaCORE, LLC license agreement, warrants to purchase 3,404 [2] Does not include an additional 98,686 [3] Does not include an additional 98,686 [4] Does not include an additional 6,199
Segment Reporting	Segment Reporting The Company operates and manages its business as one reportable and operating segment. All assets and operations are in the U.S. The Company’s Chief Executive Officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance.
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements In December 2019, the FASB issued ASU 2019-12, “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes,” which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. ASU 2019-12 is effective for fiscal years beginning after December 15, 2021. This standard was adopted on January 1, 2022 and did not have a material impact on the Company’s consolidated financial statements. ZYVERSA THERAPEUTICS, INC. NOTES TO FINANCIAL STATEMENTS In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. This new standard provides clarification and reduces diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (such as warrants) that remain equity classified after modification or exchange. This standard is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Companies should apply the new standard prospectively to modifications or exchanges occurring after the effective date of the new standard. This standard was adopted on January 1, 2022 and did not have a material impact on the Company’s consolidated financial statements. In February 2016, the FASB issued Accounting Standards Update (“ASU”) 2016-02, “Leases (Topic 842).” ASU 2016-02 requires that a lessee recognize the assets and liabilities that arise from operating leases. A lessee should recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term. For leases with a term of 12 months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and lease liabilities. In transition, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. This amendment will be effective for private companies and emerging growth companies for fiscal years beginning after December 15, 2021, and interim periods within fiscal years beginning after December 15, 2022. The FASB issued ASU No. 2018-10 “Codification Improvements to Topic 842, Leases” and ASU No. 2018-11 “Leases (Topic 842) Targeted Improvements” in July 2018, and ASU No. 2018-20 “Leases (Topic 842) - Narrow Scope Improvements for Lessors” in December 2018. ASU 2018-10 and ASU 2018-20 provide certain amendments that affect narrow aspects of the guidance issued in ASU 2016-02. ASU 2018-11 allows all entities adopting ASU 2016-02 to choose an additional (and optional) transition method of adoption, under which an entity initially applies the new leases standard at the adoption date and recognizes a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. The Company adopted ASU 2016-02 on December 31, 2022, effective January 1, 2022 and the adoption of this ASU resulted in the recording of right-of-use assets and lease liabilities for the Company’s operating leases in the approximate amounts of $ 182,732 199,642 16,910

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2023
Accounting Policies [Abstract]
Schedule of Anti-dilutive Securities Excluded From Calculation of Diluted Net Loss Per Share	The following table sets forth the outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to do so would be anti-dilutive: Schedule of Anti-dilutive Securities Excluded From Calculation of Diluted Net Loss Per Share FinancialDesignationPredecessorAndSuccessorFixedList 2023 2022 December 12, 2022 Financial Designation, Predecessor and Successor [Fixed List] Successor Successor Predecessor Successor Predecessor December 31, 2023 2022 December 12, 2022 Predecessor warrants [1] - - 8,560,561 Successor warrants [1] 9,032,739 246,534 [2] - Predecessor options - - 10,039,348 Successor options 101,752 56,950 - Successor Series A Convertible Preferred Stock 714 24,671 [3] - Successor Series B Convertible Preferred Stock 20,664 14,465 [4] - Predecessor Series A Convertible Preferred Stock - - 6,406,210 Total potentially dilutive shares 9,155,869 342,620 25,006,119 [1] As part of the InflamaCORE, LLC license agreement, warrants to purchase 3,404 [2] Does not include an additional 98,686 [3] Does not include an additional 98,686 [4] Does not include an additional 6,199

Business Combination (Tables)

Business Combination (Tables)	12 Months Ended
	Dec. 31, 2023
Business Combination and Asset Acquisition [Abstract]
Schedule of Fair Value of the Purchase Consideration	The final estimates of the acquisition-date fair value of the purchase consideration were as follows: Schedule of Fair Value of the Purchase Consideration Successor common stock $ 67,197,300 Successor warrants 12,190,015 Successor options 11,864,556 Total fair value of the purchase consideration $ 91,251,871
Schedule of Estimated Fair Values of Identifiable Net Assets Acquired Recorded as Goodwill	Schedule of Estimated Fair Values of Identifiable Net Assets Acquired Recorded as Goodwill Current assets, including cash of $ 699,324 $ 1,093,223 In-process research and development 100,086,329 Goodwill 11,895,033 Other non-current assets 64,523 Total assets acquired 113,139,108 Current liabilities 10,818,204 Deferred tax liabilities 11,069,033 Total assumed liabilities 21,887,237 Net assets acquired $ 91,251,871

Accrued Expenses and Other Cu_2

Accrued Expenses and Other Current Liabilities (Tables)	12 Months Ended
	Dec. 31, 2023
Payables and Accruals [Abstract]
Schedule of Accrued Expenses and Other Current Liabilities	As of December 31, 2023 and 2022, accrued expenses and other current liabilities consisted of the following: Schedule of Accrued Expenses and Other Current Liabilities 2023 2022 For the Years Ended December 31, 2023 2022 L&F milestone payment liability $ 500,000 $ 1,500,000 L&F Note [1] - (351,579 ) L&F, net 500,000 1,148,421 Payroll accrual 668,803 584,226 Other accrued expenses 41,969 214,229 Federal income tax payable - 106,683 Bonus accrual 536,500 - Registration delay liability [2] 7,261 - Total accrued expenses and other current liabilities $ 1,754,533 $ 2,053,559 [1] See Note 5 – “Note Receivable” and Note 8 – “Commitments and Contingencies” for details of the forgiveness of the L&F Note. [2] See Note 9 – “Stockholders’ Permanent and Temporary Equity – Effectiveness Failure” for details of the registration delay liability.

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2023
Income Tax Disclosure [Abstract]
Schedule of Provision For Income Taxes	The provision for income taxes consists of the following (benefits) provisions: Schedule of Provision For Income Taxes 2023 2022 2022 Financial Designation, Predecessor and Successor [Fixed List] Successor Successor Predecessor Successor Predecessor For the Period For the Period For the Year December 13 January 1 Ended Through Through December 31, December 31, December 12, 2023 2022 2022 Current tax benefit: Federal $ - $ - $ - State 23,240 - - Current tax benefit 23,240 - - Deferred tax benefit: Federal (19,104,800 ) (151,625 ) (2,191,344 ) State (4,468,170 ) (34,844 ) (482,283 ) Deferred tax benefit (23,572,970 ) (186,469 ) (2,673,627 ) Change in valuation allowance 14,093,900 (558,581 ) 2,673,627 Provision for income taxes $ (9,455,830 ) $ (745,050 ) $ -
Schedule of Provision For Income Taxes Differs From The Federal Statutory Rate	The provision for income taxes differs from the Federal statutory rate as follows: Schedule of Provision For Income Taxes Differs From The Federal Statutory Rate 2023 2022 2022 Financial Designation, Predecessor and Successor [Fixed List] Successor Successor Predecessor Successor Predecessor For the Period For the Period For the Year December 13 January 1 Ended Through Through December 31, December 31, December 12, 2023 2022 2022 Federal statutory rate 21.0 % 21.0 % 21.0 % State tax rate, net of federal benefit 3.8 % 3.6 % 3.6 % Permanent items (2.8 )% (1.9 %) (5.4 )% Nondeductible basis difference 0.0 % 0.0 % 0.0 % Effect of change in state rate (0.1 )% 0.0 % (0.1 )% Prior period adjustments and other 0.0 % 0.0 % (0.1 )% Change in valuation allowance (13.1 )% 68.1 % (19.0 )% Effective income tax rate 8.8 % 90.8 % 0.0 %
Schedule of Deferred Tax Assets and Liabilities	Deferred tax assets and liabilities consist of the following: Schedule of Deferred Tax Assets and Liabilities 2023 2022 December 12, 2022 Successor Successor Predecessor Successor Predecessor December 31, 2023 2022 December 12, 2022 Net operating loss carryforwards $ 9,974,075 $ 6,671,907 $ 6,639,882 Stock-based compensation expense 3,258,463 2,936,945 4,084,595 Capitalized research and development costs 2,182,104 2,421,390 2,362,939 Capitalized start-up costs 1,033,504 1,121,802 565,530 Capitalized licensing costs 647,489 687,926 689,820 Capitalized patents 351,721 288,123 273,682 Warrants 134,341 133,203 238,768 Accrued payroll 299,487 71,830 - Contributions carryforward 2,857 2,833 2,833 Operating lease liability 2,151 26,794 - Deferred tax assets 17,886,192 14,362,753 14,858,049 Valuation allowance (14,093,900 ) - (14,853,648 ) Deferred tax assets 3,792,292 14,362,753 4,401 Operating lease right-of-use asset (1,948 ) (24,236 ) - In-process research and development (4,633,535 ) (24,658,231 ) - Fixed assets (1,723 ) (4,270 ) (4,401 ) Deferred tax liabilities (4,637,206 ) (24,686,737 ) (4,401 ) Deferred tax assets, net $ (844,914 ) $ (10,323,984 ) $ -

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Schedule of Right of Use Assets and Liabilities	A summary of the Company’s right-of-use assets and liabilities is as follows: Schedule of Right of Use Assets and Liabilities Financial Designation, Predecessor and Successor [Fixed List] Successor Successor Predecessor Successor Predecessor For the Period For the Period For the Year December 13 January 1, 2022 December 31, 2023 December 31, 2022 December 12, 2022 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows used in operating activities $ 100,099 $ 4,786 $ 86,100 Right-of-use assets obtained in exchange for lease obligations Operating leases $ - $ - $ - Weighted Average Remaining Lease Term Operating leases 0.08 1.08 1.08 Weighted Average Discount Rate Operating leases 6.5 % 6.5 % 6.5 %
Schedule of Future Minimum Payments Under Lease	Future minimum payments under these operating lease agreements are as follows: Schedule of Future Minimum Payments Under Lease Amount For the year ended December 31, 2024 $ 8,703 Less: amount representing imputed interest (48 ) Total $ 8,656

Stockholders_ Permanent and T_2

Stockholders’ Permanent and Temporary Equity (Tables)	12 Months Ended
	Dec. 31, 2023
Equity [Abstract]
Schedule of Stock Options Valuation Assumptions	The grant date fair value of stock options granted during the Successor year ended December 31, 2023 and the period from December 13, 2022 through December 31, 2022 for the Successor and the period from January 1, 2022 through December 12, 2022 for the Predecessor was determined using the Black Scholes method, with the following assumptions used: Schedule of Stock Options Valuation Assumptions Successor Successor Predecessor Successor Predecessor For the Period For the Period For the Year ended December 13 January 1 December 31, 2023 December 31, 2022 December 12, 2022 Fair value of common stock on date of grant $ 15.26 78.05 n/a $ 2.27 3.00 Risk free interest rate 3.53 4.27 n/a 1.68 3.01 % Expected term (years) 5.00 6.00 n/a 3.53 6.00 Expected volatility 120 123 n/a 111 119 % Expected dividends 0.00 % n/a 0.00 %
Schedule of Stock Option Activity	A summary of the option activity for the year ended December 31, 2023 is presented below: Schedule of Stock Option Activity Weighted Weighted Average Average Remaining Aggregate Number of Exercise Life Intrinsic Options Price In Years Value Outstanding, January 1, 2023 56,999 $ 366.29 Granted 44,753 19.52 Exercised - - Forfeited - - Outstanding, December 31, 2023 101,752 $ 220.65 6.3 $ - Exercisable, December 31, 2023 56,284 $ 333.65 5.0 $ -
Schedule of Information Related to Stock Options	The following table presents information related to stock options as of December 31, 2023: Schedule of Information Related to Stock Options Options Outstanding Options Exercisable Weighted Outstanding Average Exercisable Exercise Number of Remaining Life Number of Price Options In Years Options $ 15.25 41,523 9 4,286 $ 73.85 2,858 - - $ 79.10 372 - - $ 176.05 18,952 2.1 18,952 $ 396.55 351 8.5 351 $ 405.30 20,819 5.3 20,819 $ 572.60 16,877 7.4 11,876 101,752 5.0 56,284
Summary of Warrant Activity	A summary of the warrant activity for the year ended December 31, 2023 is presented below: Summary of Warrant Activity Weighted Weighted Average Average Remaining Aggregate Number of Exercise Life Intrinsic Warrants Price In Years Value Outstanding, Janaury 1, 2023 246,594 $ 376.11 Issued [4] [4] 8,881,859 2.71 Exercised [5] [5] (203,463 ) 4.75 Forfeited (9,447 ) 32.47 Repriced - Old [1] (24,672 ) 402.50 Repriced - New [1] 141,868 70.00 Repriced - Old [2] (39,372 ) 35.00 Repriced - New [2] 39,372 5.78 Repriced - Old [3] (203,463 ) 5.78 Repriced - New [3] 203,463 4.75 Outstanding, December 31, 2023 9,032,739 $ 12.34 3.2 $ - Exercisable, December 31, 2023 8,827,273 $ 12.48 3.3 $ - [1] Warrants represent the reset of the exercise price of the PIPE Warrants to purchase 24,672 70.00 [2] Warrants represent the reset of the exercise price of certain April 28, 2023 offering warrants to purchase 39,372 5.78 [3] Warrants represent the reset of the exercise price of certain July 26, 2023 offering warrants to purchase 203,463 4.75 [4] Warrants issued exclude 270,565 0.0035 3,600,000 0.0001 [5] Warrants exercised exclude 270,565 0.0035 2,285,000 0.0001
Schedule of Information Related to Stock Warrants	The following table presents information related to stock warrants as of December 31, 2023: Schedule of Information Related to Stock Warrants Warrants Outstanding [1] Warrants Exercisable [1] Outstanding Weighted Average Exercisable Exercise Number of Remaining Life Number of Price Warrants In Years Warrants $ 1.25 8,000,000 3.2 8,000,000 $ 4.75 203,464 n/a - $ 5.78 199,555 4.5 199,555 $ 35.00 275,378 4.3 275,378 $ 70.00 139,403 4.0 139,403 $ 176.05 2,994 1.1 998 $ 241.50 36,363 3.9 36,363 $ 402.50 173,306 4.0 173,306 $ 405.30 2,270 0.3 2,270 9,032,733 3.3 8,827,273 [1] Warrants outstanding and exercisable exclude 1,315,000 0.0001

Business Organization, Nature_2

Business Organization, Nature of Operations and Risks and Uncertainties (Details Narrative)	Dec. 31, 2023 USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash FDIC insured amount	$ 250,000

Going Concern and Management__2

Going Concern and Management’s Plans (Details Narrative) - USD ($)	1 Months Ended	2 Months Ended	11 Months Ended	12 Months Ended
	Dec. 31, 2022	Mar. 15, 2024	Dec. 12, 2022	Dec. 31, 2023
Subsequent Event [Line Items]
Gross proceeds December 2023 Offering warrants				$ 1,126
Subsequent Event [Member] | December 2023 Offering [Member]
Subsequent Event [Line Items]
Gross proceeds December 2023 Offering warrants		$ 2,672,500

Schedule of Anti-dilutive Secur

Schedule of Anti-dilutive Securities Excluded From Calculation of Diluted Net Loss Per Share (Details) - shares		1 Months Ended		11 Months Ended	12 Months Ended
		Dec. 31, 2022		Dec. 12, 2022	Dec. 31, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Financial Designation, Predecessor and Successor [Fixed List]		Successor		Predecessor	Successor
Total potentially dilutive shares		342,620		25,006,119	9,155,869
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	[1]	246,534	[2]		9,032,739
Warrant [Member] | Predecessor [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	[1]			8,560,561
Share-Based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares		56,950			101,752
Share-Based Payment Arrangement, Option [Member] | Predecessor [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares				10,039,348
Series A Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares		24,671	[3]		714
Series A Convertible Preferred Stock [Member] | Predecessor [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares				6,406,210
Series B Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares		14,465	[4]		20,664
[1]As part of the InflamaCORE, LLC license agreement, warrants to purchase 3,404 98,686 98,686 6,199

Schedule of Anti-dilutive Sec_2

Schedule of Anti-dilutive Securities Excluded From Calculation of Diluted Net Loss Per Share (Details) (Parenthetical) - shares	1 Months Ended
	Dec. 31, 2022	Dec. 31, 2023	Dec. 12, 2022
Series A Warrant [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Shares available for conversion	98,686
Series A Convertible Preferred Stock [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Shares available for conversion	98,686
Series B Convertible Preferred Stock [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Shares available for conversion	6,199
Inflamacore, LlC License Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Warrants to purchase common shares	3,404	3,404	3,404

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details Narrative) - USD ($)		1 Months Ended	11 Months Ended	12 Months Ended
	Dec. 04, 2023	Dec. 31, 2022	Dec. 12, 2022	Dec. 31, 2023
Reverse stock split	the Company effected a reverse stock split of its common stock at a ratio of 1-for-35 (the “Reverse Split”). Upon the effectiveness of the Reverse Split, every 35 issued shares of common stock were reclassified and combined into one share of common stock.
Estimated useful life				5 years
Equipment		$ 52,000		$ 52,000
Accumulated depreciation		$ 34,667		$ 45,067
Financial Designation, Predecessor and Successor [Fixed List]		Successor	Predecessor	Successor
Depreciation		$ 532	$ 9,868	$ 10,400
Company valuation				85,000,000
Operating lease right of use asset		$ 98,371		7,839
Accounting Standards Update 2016-02 [Member]
Operating lease right of use asset				182,732
Operating lease liability				199,642
Deferred rent				$ 16,910

Schedule of Fair Value of the P

Schedule of Fair Value of the Purchase Consideration (Details) - Larkspur Larkspur Merger Sub Inc [Member]	1 Months Ended
	Jun. 30, 2023 USD ($)
Business Acquisition [Line Items]
Total fair value of the purchase consideration	$ 91,251,871
Common Stock [Member]
Business Acquisition [Line Items]
Total fair value of the purchase consideration	67,197,300
Warrant [Member]
Business Acquisition [Line Items]
Total fair value of the purchase consideration	12,190,015
Share-Based Payment Arrangement, Option [Member]
Business Acquisition [Line Items]
Total fair value of the purchase consideration	$ 11,864,556

Schedule of Estimated Fair Valu

Schedule of Estimated Fair Values of Identifiable Net Assets Acquired Recorded as Goodwill (Details) - USD ($)	Dec. 31, 2023	Jun. 30, 2023	Dec. 31, 2022
Business Combination and Asset Acquisition [Abstract]
Current assets, including cash of $699,324		$ 1,093,223
In-process research and development		100,086,329
Goodwill		11,895,033	$ 11,895,033
Other non-current assets		64,523
Total assets acquired		113,139,108
Current liabilities		10,818,204
Deferred tax liabilities		11,069,033
Total assumed liabilities		21,887,237
Net assets acquired		$ 91,251,871

Schedule of Estimated Fair Va_2

Schedule of Estimated Fair Values of Identifiable Net Assets Acquired Recorded as Goodwill (Details) (Parentheticals)	Jun. 30, 2023 USD ($)
Business Combination and Asset Acquisition [Abstract]
Cash	$ 699,324

Business Combination (Details N

Business Combination (Details Narrative)	1 Months Ended	11 Months Ended	12 Months Ended
	Dec. 31, 2022 USD ($) shares	Dec. 12, 2022 USD ($) shares	Dec. 31, 2023 USD ($) shares
Business Acquisition [Line Items]
Share issued on conversion	191,992
Financial Designation, Predecessor and Successor [Fixed List]	Successor	Predecessor	Successor
Share exchange ration	176.28
Number of options outstanding	56,999		101,752
Goodwill impairment | $			$ 11,895,033
Impairment charge for other indefinite-lived intangible assets | $			$ 81,438,426
Share-Based Payment Arrangement, Option [Member]
Business Acquisition [Line Items]
Share exchange ration	176.28
Number of options outstanding	56,950
Replacement of Options			1,731,237
Share-Based Payment Arrangement, Option [Member] | Predecessor [Member]
Business Acquisition [Line Items]
Number of options outstanding		10,039,348
Warrant [Member]
Business Acquisition [Line Items]
Share exchange ration	176.28
Number of warrants outstanding	48,561
Warrants outstanding | $			$ 584,260
Warrant [Member] | Predecessor [Member]
Business Acquisition [Line Items]
Number of warrants outstanding		8,560,561
Larkspur Larkspur Merger Sub Inc [Member]
Business Acquisition [Line Items]
Share exchange		33,845,335
Share issued on conversion		16,681
Larkspur Larkspur Merger Sub Inc [Member] | Permanent Equity Shares [Member]
Business Acquisition [Line Items]
Share exchange		33,514,004
Larkspur Larkspur Merger Sub Inc [Member] | Temporary Shares [Member]
Business Acquisition [Line Items]
Share exchange		331,331

Note Receivable (Details Narrat

Note Receivable (Details Narrative) - USD ($)	Mar. 29, 2023	Feb. 28, 2023	Dec. 13, 2020
License Agreement [Member] | L&F Research LLC [Member] | Waiver A [Member]
Short-Term Debt [Line Items]
Cash payment	$ 648,421	$ 648,421
L&F Note [Member]
Short-Term Debt [Line Items]
Debt instrument face amount			$ 351,579
Debt instrument interest rate			1.17%
Prepay of note, description			L&F is required to immediately prepay the L&F Note and all accrued and unpaid interest on the L&F Note with the following: (a) 100% of the proceeds of the second $500,000 of milestone payments paid by ZyVersa to L&F pursuant to the terms of the license agreement (See Note 8 - Commitments and Contingencies), (b) 100% of the gross proceeds from the sale of common stock by L&F to ZyVersa pursuant to the terms of the Put Option (See Note 9 – Stockholders’ Permanent and Temporary Equity), (c) 100% of the gross proceeds in excess of $1.00 per share from the sale of ZyVersa common stock by L&F to any party other than ZyVersa and (d) proceeds received in connection with certain liquidation events as defined in the agreement. Commencing on December 13, 2021 and, so long as the principal amount of the L&F Note remains outstanding, on each December 13 through December 13, 2025, the Company will pay L&F an annual administrative fee equal to $6,000.
Milestone payments			$ 500,000
Administrative fee			$ 6,000

Schedule of Accrued Expenses an

Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($)		Dec. 31, 2023	Dec. 31, 2022
Payables and Accruals [Abstract]
L&F milestone payment liability		$ 500,000	$ 1,500,000
L&F Note	[1]		(351,579)
L&F, net		500,000	1,148,421
Payroll accrual		668,803	584,226
Other accrued expenses		41,969	214,229
Federal income tax payable			106,683
Bonus accrual		536,500
Registration delay liability	[2]	7,261
Total accrued expenses and other current liabilities		$ 1,754,533	$ 2,053,559
[1]See Note 5 – “Note Receivable” and Note 8 – “Commitments and Contingencies” for details of the forgiveness of the L&F Note.[2]See Note 9 – “Stockholders’ Permanent and Temporary Equity – Effectiveness Failure” for details of the registration delay liability.

Schedule of Provision For Incom

Schedule of Provision For Income Taxes (Details) - USD ($)	1 Months Ended	11 Months Ended	12 Months Ended
	Dec. 31, 2022	Dec. 12, 2022	Dec. 31, 2023
Income Tax Disclosure [Abstract]
Financial Designation, Predecessor and Successor [Fixed List]	Successor	Predecessor	Successor
Current tax benefit:
Federal
State			23,240
Current tax benefit			23,240
Deferred tax benefit:
Federal	(151,625)	(2,191,344)	(19,104,800)
State	(34,844)	(482,283)	(4,468,170)
Deferred tax benefit	(186,469)	(2,673,627)	(23,572,970)
Change in valuation allowance	(558,581)	2,673,627	14,093,900
Provision for income taxes	$ (745,050)		$ (9,455,830)

Schedule of Provision For Inc_2

Schedule of Provision For Income Taxes Differs From The Federal Statutory Rate (Details)	1 Months Ended	11 Months Ended	12 Months Ended
	Dec. 31, 2022	Dec. 12, 2022	Dec. 31, 2023
Income Tax Disclosure [Abstract]
Financial Designation, Predecessor and Successor [Fixed List]	Successor	Predecessor	Successor
Federal statutory rate	21%	21%	21%
State tax rate, net of federal benefit	3.60%	3.60%	3.80%
Permanent items	(1.90%)	(5.40%)	(2.80%)
Nondeductible basis difference	0%	0%	0%
Effect of change in state rate	0%	(0.10%)	(0.10%)
Prior period adjustments and other	0%	(0.10%)	0%
Change in valuation allowance	68.10%	(19.00%)	(13.10%)
Effective income tax rate	90.80%	0%	8.80%

Schedule of Deferred Tax Assets

Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)	1 Months Ended	11 Months Ended	12 Months Ended
	Dec. 31, 2022	Dec. 12, 2022	Dec. 31, 2023
Income Tax Disclosure [Abstract]
Financial Designation, Predecessor and Successor [Fixed List]	Successor	Predecessor	Successor
Net operating loss carryforwards	$ 6,671,907	$ 6,639,882	$ 9,974,075
Stock-based compensation expense	2,936,945	4,084,595	3,258,463
Capitalized research and development costs	2,421,390	2,362,939	2,182,104
Capitalized start-up costs	1,121,802	565,530	1,033,504
Capitalized licensing costs	687,926	689,820	647,489
Capitalized patents	288,123	273,682	351,721
Warrants	133,203	238,768	134,341
Accrued payroll	71,830		299,487
Contributions carryforward	2,833	2,833	2,857
Operating lease liability	26,794		2,151
Deferred tax assets	14,362,753	14,858,049	17,886,192
Valuation allowance		(14,853,648)	(14,093,900)
Deferred tax assets	14,362,753	4,401	3,792,292
Operating lease right-of-use asset	(24,236)		(1,948)
In-process research and development	(24,658,231)		(4,633,535)
Fixed assets	(4,270)	(4,401)	(1,723)
Deferred tax liabilities	(24,686,737)	(4,401)	(4,637,206)
Deferred tax assets, net	$ (10,323,984)		$ (844,914)

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	1 Months Ended	11 Months Ended	12 Months Ended
	Dec. 31, 2022	Dec. 12, 2022	Dec. 31, 2023
Income Tax Disclosure [Abstract]
Financial Designation, Predecessor and Successor [Fixed List]	Successor	Predecessor	Successor
Net operating loss carry forwards, federal	$ 27,515,427	$ 27,385,445	$ 40,807,990
Net operating loss carry forwards, state	20,567,703	20,458,902	32,322,138
Increase in valuation allowance		2,673,627
Valuation allowance		14,853,648	14,093,900
Change in valuation allowance	$ 558,581	$ (2,673,627)	(14,093,900)
Deferred tax liabilities valuation allowance			$ 14,093,900

Schedule of Right of Use Assets

Schedule of Right of Use Assets and Liabilities (Details) - USD ($)	1 Months Ended	11 Months Ended	12 Months Ended
	Dec. 31, 2022	Dec. 12, 2022	Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Financial Designation, Predecessor and Successor [Fixed List]	Successor	Predecessor	Successor
Operating cash flows used in operating activities	$ 4,786	$ 86,100	$ 100,099
Operating leases
Weighted average remaining lease term	1 year 29 days	1 year 29 days	29 days
Weighted average discount rate	6.50%	6.50%	6.50%

Schedule of Future Minimum Paym

Schedule of Future Minimum Payments Under Lease (Details)	Dec. 31, 2023 USD ($)
Commitments and Contingencies Disclosure [Abstract]
For the year ended December 31, 2024	$ 8,703
Less: amount representing imputed interest	(48)
Total	$ 8,656

Commitments and Contingencies_2

Commitments and Contingencies (Details Narrative)

1 Months Ended

11 Months Ended

12 Months Ended

Jan. 30, 2024 USD ($)

Jan. 15, 2024 USD ($)

Mar. 29, 2023 USD ($)

Feb. 28, 2023 USD ($)

Dec. 23, 2022 USD ($)

Aug. 26, 2022 USD ($)

Mar. 07, 2022 USD ($)

Jan. 31, 2020 USD ($) shares

Jan. 09, 2020 USD ($)

Apr. 18, 2019 USD ($) $ / shares shares

Jan. 18, 2019 USD ($) ft²

Dec. 15, 2015 USD ($) $ / shares shares

Dec. 31, 2022 USD ($) $ / shares shares

Dec. 12, 2022 USD ($)

Dec. 31, 2023 USD ($)

Dec. 31, 2021 USD ($)

Dec. 31, 2020 USD ($)

Jul. 26, 2023 shares

May 10, 2022 $ / shares

Loss Contingencies [Line Items]

License agreements up front cash payment

$ 200,000

Aggregate milestone cash payments

$ 1,000,000

$ 22,500,000

21,500,000

$ 500,000

$ 1,500,000

Second license agreement milestone

$ 2,500,000

Cash payment exercise price withheld

351,579

Aggregate milestone cash payments, description

the first milestone payment of $200,000 is triggered by the submission of an investigational new drug application for the first indication of a therapeutic licensed product). ZyVersa is required to pay sales royalties to InflamaCORE between 5% and 10%, which expire upon the latest of: (a) expiration of the last-to-expire of a patent or (b) expiration of regulatory exclusivity, as defined in the agreement. ZyVersa is required to pay sales royalties to the University of Miami between 3% and 6%.

Operating lease rent expense

$ 7,795

$ 148,881

$ 154,841

Financial Designation, Predecessor and Successor [Fixed List]

Successor

Predecessor

Successor

Subsequent Event [Member]

Loss Contingencies [Line Items]

Operating lease rent expense

$ 112,064

License Agreement [Member] | L&F Research LLC [Member]

Loss Contingencies [Line Items]

Aggregate milestone cash payments

$ 1,500,000

$ 1,500,000

$ 1,500,000

Aggregate milestone cash payments, description

the Company and L&F executed an Amendment and Restatement Agreement that waived L&F’s right to terminate the L&F License Agreement or any other remedies, for non-payment of the First Milestone Payment, until (a) March 31, 2023 as to $1,000,000 of such milestone payments (“Waiver A”) and (b) January 31, 2024 as to $500,000 of milestone payments (“Waiver B”).

License Agreement [Member] | L&F Research LLC [Member] | Waiver A [Member]

Loss Contingencies [Line Items]

Debt forgiveness

$ 351,579

$ 351,579

Cash payment

$ 648,421

$ 648,421

Maturity date

Mar. 31, 2023

License Agreement [Member] | L&F Research LLC [Member] | Waiver B [Member]

Loss Contingencies [Line Items]

Cash payment

$ 500,000

Maturity date

Jan. 31, 2024

Net proceeds from issuance of equity capital

$ 30,000,000

License Agreement [Member] | L&F Research LLC [Member] | Waiver B [Member] | Subsequent Event [Member]

Loss Contingencies [Line Items]

Cash payment

$ 500,000

Phase 1/2 Milestone [Member]

Loss Contingencies [Line Items]

Aggregate milestone cash payments

500,000

First Anniversary Milestone [Member]

Loss Contingencies [Line Items]

Aggregate milestone cash payments

$ 500,000

Predecessor [Member]

Loss Contingencies [Line Items]

License agreements up front cash payment

$ 346,321

Common stock fair value | shares

200,000

Grant date fair value

$ 460,000

Number of operating lease square feet | ft²

3,500

Lease cost

$ 89,000

Operating lease rent expense

$ 497,000

Warrant [Member]

Loss Contingencies [Line Items]

Aggregate common stock shares | shares

2,270

39,372

Aggregate common stock exercise price share | $ / shares

$ 405.30

$ 402.50

$ 3.20

Fair value of warrant

$ 584,260

Warrant [Member] | Predecessor [Member]

Loss Contingencies [Line Items]

Aggregate common stock shares | shares

175,789

400,000

878,947

351,578

Aggregate common stock exercise price share | $ / shares

$ 2.30

$ 1

Grant date fair value

$ 153,324

$ 766,384

Warrant exercisable

5 years

Issue date fair value

$ 815,822

Warrant One [Member] | Predecessor [Member]

Loss Contingencies [Line Items]

Aggregate common stock shares | shares

600,000

351,579

Fair value of warrant

$ 306,411

Five Year Warrant [Member] | Predecessor [Member]

Loss Contingencies [Line Items]

Aggregate common stock shares | shares

1,000,000

Minimum [Member]

Loss Contingencies [Line Items]

Percentage of product sales

5%

Maximum [Member]

Loss Contingencies [Line Items]

Percentage of product sales

10%

Schedule of Stock Options Valua

Schedule of Stock Options Valuation Assumptions (Details) - $ / shares	1 Months Ended	11 Months Ended	12 Months Ended
	Dec. 31, 2022	Dec. 12, 2022	Dec. 31, 2023
Financial Designation, Predecessor and Successor [Fixed List]	Successor	Predecessor	Successor
Expected dividends		0%	0%
Minimum [Member]
Fair value of common stock on date of grant		$ 2.27	$ 15.26
Risk free interest rate		1.68%	3.53%
Expected term (years)		3 years 6 months 10 days	5 years
Expected volatility		111%	120%
Maximum [Member]
Fair value of common stock on date of grant		$ 3	$ 78.05
Risk free interest rate		3.01%	4.27%
Expected term (years)		6 years	6 years
Expected volatility		119%	123%

Schedule of Stock Option Activi

Schedule of Stock Option Activity (Details)	12 Months Ended
	Dec. 31, 2023 USD ($) $ / shares shares
Equity [Abstract]
Number of options, outstanding beginning balance | shares	56,999
Weighted average exercise price, beginning balance | $ / shares	$ 366.29
Number of options, granted | shares	44,753
Weighted average exercise price, granted | $ / shares	$ 19.52
Number of options, exercised | shares
Weighted average exercise price, exercised | $ / shares
Number of options, forfeited | shares
Weighted average exercise price, forfeited | $ / shares
Number of options, outstanding ending balance | shares	101,752
Weighted average exercise price, ending balance | $ / shares	$ 220.65
Weighted average remaining life in years, outstanding	6 years 3 months 18 days
Aggregate intrinsic value, ending balance | $
Number of options, exercisable ending balance | shares	56,284
Weighted average exercise price, Exercisable | $ / shares	$ 333.65
Weighted average remaining life in years, exercisable	5 years
Aggregate intrinsic value, exercisable | $

Schedule of Information Related

Schedule of Information Related to Stock Options (Details) - $ / shares	12 Months Ended
	Dec. 31, 2023	May 24, 2023	Mar. 10, 2023	Jan. 27, 2023
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options outstanding, exercise price		$ 15.25	$ 79.10	$ 73.85
Options outstanding, Number of options	101,752	41,523	372	2,858
Options exercisable, weighted average remaining life in life	5 years
Options exercisable, Number of options	56,284
Exercise Price One [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options outstanding, exercise price	$ 15.25
Options outstanding, Number of options	41,523
Options exercisable, weighted average remaining life in life	9 years
Options exercisable, Number of options	4,286
Exercise Price Two [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options outstanding, exercise price	$ 73.85
Options outstanding, Number of options	2,858
Options exercisable, Number of options
Exercise Price Three [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options outstanding, exercise price	$ 79.10
Options outstanding, Number of options	372
Options exercisable, Number of options
Exercise Price Four [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options outstanding, exercise price	$ 176.05
Options outstanding, Number of options	18,952
Options exercisable, weighted average remaining life in life	2 years 1 month 6 days
Options exercisable, Number of options	18,952
Exercise Price Five [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options outstanding, exercise price	$ 396.55
Options outstanding, Number of options	351
Options exercisable, weighted average remaining life in life	8 years 6 months
Options exercisable, Number of options	351
Exercise Price Six [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options outstanding, exercise price	$ 405.30
Options outstanding, Number of options	20,819
Options exercisable, weighted average remaining life in life	5 years 3 months 18 days
Options exercisable, Number of options	20,819
Exercise Price Seven [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options outstanding, exercise price	$ 572.60
Options outstanding, Number of options	16,877
Options exercisable, weighted average remaining life in life	7 years 4 months 24 days
Options exercisable, Number of options	11,876

Summary of Warrant Activity (De

Summary of Warrant Activity (Details)	12 Months Ended
	Dec. 31, 2023 USD ($) $ / shares shares
Equity [Abstract]
Number of warrants, outstanding beginning balance | shares	246,594
Weighted average exercise price, beginning balance | $ / shares	$ 376.11
Number of warrants, granted | shares	8,881,859	[1]
Weighted average exercise price, granted | $ / shares	$ 2.71	[1]
Number of warrants, exercised | shares	(203,463)	[2]
Weighted average exercise price, exercised | $ / shares	$ 4.75	[2]
Number of warrants, forfeited | shares	(9,447)
Weighted average exercise price, forfeited | $ / shares	$ 32.47
Number of warrants, repriced - old | shares	(24,672)	[3]
Weighted average Repriced price | $ / shares	$ 402.50	[3]
Number of warrants, repriced - new | shares	141,868	[3]
Weighted average repriced price | $ / shares	$ 70	[3]
Number of warrants, repriced - old two | shares	(39,372)	[4]
Weighted average Repriced price two | $ / shares	$ 35	[4]
Number of warrants, repriced - new two | shares	39,372	[4]
Weighted average repriced price new two | $ / shares	$ 5.78	[4]
Number of warrants, repriced - old three | shares	(203,463)	[5]
Weighted average Repriced price three | $ / shares	$ 5.78	[5]
Number of warrants, repriced - new three | shares	203,463	[5]
Weighted average repriced price new three | $ / shares	$ 4.75	[5]
Number of warrants, outstanding ending balance | shares	9,032,739
Weighted average exercise price, ending balance | $ / shares	$ 12.34
Weighted average remaining life in years, outstanding	3 years 2 months 12 days
Aggregate intrinsic value, ending balance | $
Number of warrants, exercisable ending balance | shares	8,827,273
Weighted average exercise price, Exercisable | $ / shares	$ 12.48
Weighted average remaining life in years, exercisable	3 years 3 months 18 days
Aggregate intrinsic value, exercisable | $
[1]Warrants issued exclude 270,565 0.0035 3,600,000 0.0001 270,565 0.0035 2,285,000 0.0001 24,672 70.00 39,372 5.78 203,463 4.75

Summary of Warrant Activity (_2

Summary of Warrant Activity (Details) (Parenthetical) - $ / shares				12 Months Ended
		Jul. 26, 2023	Apr. 28, 2023	Dec. 31, 2023
Class of Warrant or Right [Line Items]
Purchase of warrants shares	[1]			(24,672)
Purchase of warrants per share	[1]			$ 70
Number of warrants, issued	[2]			8,881,859
Number of warrants, exercised	[3]			203,463
PIPE Warrants [Member]
Class of Warrant or Right [Line Items]
Purchase of warrants shares				24,672
Purchase of warrants per share				$ 70
April 28, 2023 Offering Warrants [Member]
Class of Warrant or Right [Line Items]
Purchase of warrants shares			39,372
Purchase of warrants per share			$ 5.78
July 26, 2023 Offering Warrants [Member]
Class of Warrant or Right [Line Items]
Purchase of warrants shares		203,463
Purchase of warrants per share		$ 4.75
July Pre Funded Warrants [Member]
Class of Warrant or Right [Line Items]
Number of warrants, issued				270,565
Exercise price				$ 0.0035
December 2023 Pre Funded Warrants [Member]
Class of Warrant or Right [Line Items]
Number of warrants, issued				3,600,000
Exercise price				$ 0.0001
July 2023 Pre-Funded Warrants [Member]
Class of Warrant or Right [Line Items]
Exercise price				$ 0.0035
Number of warrants, exercised				270,565
December 2023 Pre-Funded Warrants [Member]
Class of Warrant or Right [Line Items]
Exercise price				$ 0.0001
Number of warrants, exercised				2,285,000
[1]Warrants represent the reset of the exercise price of the PIPE Warrants to purchase 24,672 70.00 270,565 0.0035 3,600,000 0.0001 270,565 0.0035 2,285,000 0.0001

Schedule of Information Relat_2

Schedule of Information Related to Stock Warrants (Details) - $ / shares		12 Months Ended
		Dec. 31, 2023	Dec. 31, 2022
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of warrants, outstanding		9,032,739	246,594
Number of warrants, exercisable		8,827,273
Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of warrants, outstanding	[1]	9,032,733
Warrant exercisable, weighted average remaining life in life	[1]	3 years 3 months 18 days
Number of warrants, exercisable	[1]	8,827,273
Exercise Price One [Member] | Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Weighted average exercise price, outstanding	[1]	$ 1.25
Number of warrants, outstanding	[1]	8,000,000
Warrant exercisable, weighted average remaining life in life	[1]	3 years 2 months 12 days
Number of warrants, exercisable	[1]	8,000,000
Exercise Price Two [Member] | Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Weighted average exercise price, outstanding	[1]	$ 4.75
Number of warrants, outstanding	[1]	203,464
Number of warrants, exercisable	[1]
Exercise Price Three [Member] | Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Weighted average exercise price, outstanding	[1]	$ 5.78
Number of warrants, outstanding	[1]	199,555
Warrant exercisable, weighted average remaining life in life	[1]	4 years 6 months
Number of warrants, exercisable	[1]	199,555
Exercise Price Four [Member] | Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Weighted average exercise price, outstanding	[1]	$ 35
Number of warrants, outstanding	[1]	275,378
Warrant exercisable, weighted average remaining life in life	[1]	4 years 3 months 18 days
Number of warrants, exercisable	[1]	275,378
Exercise Price Five [Member] | Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Weighted average exercise price, outstanding	[1]	$ 70
Number of warrants, outstanding	[1]	139,403
Warrant exercisable, weighted average remaining life in life	[1]	4 years
Number of warrants, exercisable	[1]	139,403
Exercise Price Six [Member] | Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Weighted average exercise price, outstanding	[1]	$ 176.05
Number of warrants, outstanding	[1]	2,994
Warrant exercisable, weighted average remaining life in life	[1]	1 year 1 month 6 days
Number of warrants, exercisable	[1]	998
Exercise Price Seven [Member] | Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Weighted average exercise price, outstanding	[1]	$ 241.50
Number of warrants, outstanding	[1]	36,363
Warrant exercisable, weighted average remaining life in life	[1]	3 years 10 months 24 days
Number of warrants, exercisable	[1]	36,363
Exercise Price Eight [Member] | Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Weighted average exercise price, outstanding	[1]	$ 402.50
Number of warrants, outstanding	[1]	173,306
Warrant exercisable, weighted average remaining life in life	[1]	4 years
Number of warrants, exercisable	[1]	173,306
Exercise Price Nine [Member] | Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Weighted average exercise price, outstanding	[1]	$ 405.30
Number of warrants, outstanding	[1]	2,270
Warrant exercisable, weighted average remaining life in life	[1]	3 months 18 days
Number of warrants, exercisable	[1]	2,270
[1]Warrants outstanding and exercisable exclude 1,315,000 0.0001

Schedule of Information Relat_3

Schedule of Information Related to Stock Warrants (Details) (Parenthetical)	Dec. 31, 2023 $ / shares shares
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of warrants outstanding and exercisable | shares	8,827,273
Weighted average exercise price, Exercisable | $ / shares	$ 12.48
Prefunded Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of warrants outstanding and exercisable | shares	1,315,000
Weighted average exercise price, Exercisable | $ / shares	$ 0.0001

Stockholders_ Permanent and T_3

Stockholders’ Permanent and Temporary Equity (Details Narrative) - USD ($)																												1 Months Ended	11 Months Ended	12 Months Ended
		Dec. 11, 2023	Oct. 31, 2023	Sep. 18, 2023	Sep. 14, 2023	Aug. 04, 2023	Aug. 02, 2023	Jul. 26, 2023	Jun. 05, 2023	May 24, 2023	Apr. 28, 2023	Mar. 29, 2023	Mar. 10, 2023	Feb. 28, 2023	Jan. 27, 2023	Jan. 02, 2023	Dec. 12, 2022	Dec. 06, 2022	Sep. 16, 2022	Aug. 31, 2022	Jul. 08, 2022	May 10, 2022	Mar. 31, 2022	Dec. 13, 2020	Jan. 31, 2020	Apr. 18, 2019	Dec. 15, 2015	Dec. 31, 2022	Dec. 12, 2022	Dec. 31, 2023		Nov. 30, 2023	Feb. 20, 2023
Subsidiary, Sale of Stock [Line Items]
Increase in authorised number of shares issued																												250,000,000		250,000,000		110,000,000
Common stock, par value																												$ 0.0001		$ 0.0001		$ 0.0001
Preferred stock, shares authorized																												1,000,000		1,000,000		1,000,000
Preferred stock, par value																												$ 0.0001		$ 0.0001		$ 0.0001
Increase in authorised number of shares issued																														251,000,000		111,000,000
Conversion of shares issued																												191,992
Fair value for general and administrative expesne																												$ 420,174	$ 7,605,205	$ 11,213,201
Issuance costs																														2,417,095
Legal costs				$ 16,131
Proceeds from sale of equity																														18,114,193
Reclassification shares of common stock value classified as temporary to permanent equity																												$ 331,331
Placement agent fees				57,980
Number of options outstanding																												56,999		101,752
Conversion price											$ 70
Deemed dividend																														$ 32,373
Common stock exercisable upon reset of Series A warrants
Satisfaction of company liabilities																														$ 5,062,000
Stock based compensation expense																												$ 56,333	$ 3,524,801	1,192,963
Unrecognized stock-based compensation expense																												2,957,047		$ 1,027,460
weighted average period																													1 year 7 months 6 days	1 year 8 months 12 days
Expire years, granted options										ten			ten		ten
Number of options issued										41,523			372		2,858															101,752
Options granted that vest over three years										$ 499,660					$ 184,426
Vesting period															3 years
Options issued, exercise price										$ 15.25			$ 79.10		$ 73.85
Aggregate grant date value										$ 555,004			$ 23,770
Shares issued													143
Vesting period										3 years
Options vesting immediately										$ 55,344
Company valuation																														85,000,000
Incremental Fair Valu				134,591
Gross proceeds pre-funded warrants																														$ 1,126
Exercise price	[1]																													$ 70
Grant of new warrants																														5 years
Warrant modification costs				$ 134,591
Percentage of registration delay payments																																	1.50%
Effectiveness failure interest rate																																	2%
Accrued registration delay payments																														$ 7,261
Research and Development Expense [Member]
Subsidiary, Sale of Stock [Line Items]
Stock based compensation expense																												7,808	673,160	132,767
General and Administrative Expense [Member]
Subsidiary, Sale of Stock [Line Items]
Stock based compensation expense																												$ 48,525	$ 2,851,641	$ 1,060,196
Series A Warrant [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants to purchase common shares						2,465											6,406,210												6,406,210
Warrant exercise price						$ 2
Aggregate common stock of warrant exercise price share																				$ 3.20
Warrant, Exercise Price, Decrease																				1.37
Five Year Warrant [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants to purchase common shares																	36,340												36,340
Aggregate common stock of warrant exercise price share																	$ 241.50
Series B Warrants [Member]
Subsidiary, Sale of Stock [Line Items]
Exercise floor price reset											245
July 2023 Warrants [Member]
Subsidiary, Sale of Stock [Line Items]
Exercise price				$ 4.75
Warrant [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants to purchase common shares								39,372																		2,270
Warrant exercise price																						$ 3.20				$ 405.30		$ 402.50
Shares issued, price per share																												$ 1,000
Incremental Fair Valu								$ 47,300
Exercise price				$ 4.75
Grant of new warrants				5 years 6 months
Common Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Issuance costs					$ 208,702
Shares issued for services																														104,571
Conversion price											$ 70
Reclassification of formerly redeemable common stock																														1,880
Deemed dividend											$ 1,400,000
Common stock exercisable upon reset of Series A warrants											141,861
Warrant inducement offer - exercise proceeds, shares					203,463																									203,463	[2]
Gross proceeds					$ 966,400
Investor [Member] | Series A Convertible Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Reclassification of formerly redeemable common stock						150
Cash payment						$ 230,000
Investor [Member] | Prefunded Warrants [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants to purchase common shares							270,565
Warrant exercise price							$ 0.0035
Gross proceeds pre-funded warrants							$ 947
Series A Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Preferred stock, shares authorized																												8,635		8,635
Conversion of shares issued											35
Warrants to purchase common shares																												24,671
Preferred stock sold																												8,635
Net proceeds																												$ 8,635,000
Preferred stock conversion price per share																				2.78		3.14
Preferred stock conversion price per share																				$ 1.19		$ 2.78
Incremental fair value of stock and warrants																				$ 9,684,637		$ 331,200
Number of options outstanding																	2,427,832												2,427,832
Conversion of shares converted											500
Conversion price																												$ 350
Conversion basis																												(a) $70.00; and (b) the lowest price of any subsequent offerings of securities at a price less than the conversion price
Deemed dividend											$ 37,000
Remaining shares with conversion floor price reset											235
Preferred stock, shares designated																												8,635		50
Series A Preferred Stock [Member] | Common Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Conversion price											$ 350
Series A Preferred Stock [Member] | Investor [Member]
Subsidiary, Sale of Stock [Line Items]
Preferred stock sold																		174,776	222,929		94,393		133,541
Preferred stock price per share																		$ 3.14	$ 3.14		$ 3.14		$ 3.14
Net proceeds																							$ 392,301
Proceeds from related party debt																							$ 100,000
Gross proceeds																		$ 548,805	$ 700,000		$ 296,400
Placement agent fees																		$ 2,000	$ 16,000		$ 21,200
Series B Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Preferred stock, shares authorized																												5,062		5,062
Shares issued, price per share																														$ 1,000
Deemed dividend											$ 100,000
Preferred stock, shares designated																												5,062		5,062
Shares conversion price																														$ 350
Series B Preferred Stock [Member] | Common Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Conversion price											$ 350
Shares issued in connection with the Business Combination											5,062
Maximum [Member] | Investor [Member] | Series A Convertible Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Remaining shares before redemption						200
Maximum [Member] | Three Investor [Member] | Warrant [Member]
Subsidiary, Sale of Stock [Line Items]
Warrant exercise price								$ 5.78
Minimum [Member] | Three Investor [Member] | Warrant [Member]
Subsidiary, Sale of Stock [Line Items]
Warrant exercise price								$ 35
Minimum [Member] | Series B Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Shares conversion price																														$ 245
Private Placement [Member]
Subsidiary, Sale of Stock [Line Items]
Shares issued									86,976
Issuance costs									$ 1,200,000
Shares held by investors									56,507
Fair value for general and administrative expesne																														$ 1,156,778
April 2023 Offering [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants to purchase common shares											24,671
Warrant exercise price											$ 402.50
Proceeds from Registered Offering to Redeem Series A Preferred Stock											$ 10,500,000
Reclassification of formerly redeemable common stock											8,400
Net carrying amount											$ 3,700,000
Deemed dividend											$ 6,400,000
Exercise floor price reset											$ 70
Larkspur Larkspur Merger Sub Inc [Member]
Subsidiary, Sale of Stock [Line Items]
Convertible notes																	$ 3,961,000												$ 3,961,000
Accrued interest																	709,608												709,608
Derivative liabilities																	$ 1,167,601												$ 1,167,601
Common stock convertible																													2,940,537
Conversion of shares issued																													16,681
Conversion price																	$ 1.58835												$ 1.58835
Conversion basis																													(80% of the $1.98542 fair value per share of the Predecessor common stock which was determined using the Business Combination exchange ratio of 176.28)
Conversion of shares converted																													33,845,335
2014 Equity Incentive Plan [Member]
Subsidiary, Sale of Stock [Line Items]
Common stock, shares authorized																	102,651												102,651
Equity incentive plan, description																													The number of shares of common stock available for issuance under the 2014 Plan shall automatically increase on the first trading day of January each calendar year during the term of the 2014 Plan, beginning with calendar year 2019, by an amount equal to five percent (5%) of the total number of shares of common stock outstanding on the last trading day in December of the immediately preceding calendar year.
2022 Omnibus Equity Incentive Plan [Member]
Subsidiary, Sale of Stock [Line Items]
Common stock, shares authorized																												31,138
Common stock share increase			114,286
Common stock share increase			155,809													41,523
Available for future issuance																														114,286
Marketing Agreements [Member]
Subsidiary, Sale of Stock [Line Items]
Shares issued for services																														104,571
Prepaid expense fair value of shares																														$ 671,620
April 2023 Offering [Member]
Subsidiary, Sale of Stock [Line Items]
Shares issued											314,729
Warrants to purchase common shares											314,729
Proceeds from sale of equity											$ 11,000,000
Warrant exercise price											$ 35
Issuance costs											$ 1,184,482
Placement fee											440,620
Legal costs											455,332
Professional fees											259,774
Other Offering costs											$ 28,756
July 2023 Prefunded Warrants [Member]
Subsidiary, Sale of Stock [Line Items]
Shares issued								93,030
Warrants to purchase common shares								270,565
Warrant exercise price								$ 5.78
Share price								$ 0.0035
Exercise term								5 years
July 2023 Warrants [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants to purchase common shares								363,636
Warrant exercise price								$ 5.78
July 2023 Offering [Member]
Subsidiary, Sale of Stock [Line Items]
Issuance costs								$ 523,115
Placement fee								125,943
Legal costs								236,091
Professional fees								87,037
Other Offering costs								26,744
Proceeds from sale of equity								2,100,000
Fair value of warrants								$ 47,300
July Pre Funded Warrants [Member]
Subsidiary, Sale of Stock [Line Items]
Warrant exercise price								$ 0.0035
December 2023 Prefunded Warrants [Member]
Subsidiary, Sale of Stock [Line Items]
Shares issued		400,000
Warrants to purchase common shares		3,600,000
Warrant exercise price		$ 0.0001
December 2023 Series A Warrants [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants to purchase common shares		4,000,000
Warrant exercise price		$ 1.25
Exercise term		5 years
December 2023 Series B Warrants [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants to purchase common shares		4,000,000
Warrant exercise price		$ 1.25
Exercise term		18 months
December 2023 Offering [Member]
Subsidiary, Sale of Stock [Line Items]
Proceeds from sale of equity		$ 5,000,000
Issuance costs		653,514
Placement fee		299,978
Legal costs		232,336
Professional fees		94,325
Other Offering costs		$ 26,875
License Agreement [Member] | L&F Research LLC [Member]
Subsidiary, Sale of Stock [Line Items]
Conversion of shares issued																													1,880
Share price																	$ 176.28							$ 1					$ 176.28
Reclassification shares of common stock																	331,331												331,331
License Agreement [Member] | L&F Research LLC [Member] | Waiver A [Member]
Subsidiary, Sale of Stock [Line Items]
Reclassification shares of common stock												1,880
Debt forgiveness												$ 351,579		$ 351,579
Cash payment												648,421		$ 648,421
Reclassification shares of common stock value classified as temporary to permanent equity												$ 331,331
License Agreement [Member] | L&F Research LLC [Member] | Maximum [Member]
Subsidiary, Sale of Stock [Line Items]
Reclassification shares of common stock value classified as temporary to permanent equity																								331,331
Total consideration																								$ 331
Commencement Date [Member] | Series A Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Conversion basis																												The conversion price also resets at both 90 days and 150 days following the effectiveness of the registration of the Successor Series A Preferred Stock (each a “Commencement Date”) to the greater of (a) $70.00; and (b) 85% of the lowest of the ten consecutive daily volume-weighted average prices commencing on, and including, each Commencement Date
Predecessor [Member]
Subsidiary, Sale of Stock [Line Items]
Increase in authorised number of shares issued																																75,000,000
Common stock, par value																																$ 0.00001
Preferred stock, shares authorized																																5,000,000
Preferred stock, par value																																$ 0.00001
Shares issued																										200,000
Issuance costs																										$ 460,000
Company valuation																													$ 85,000,000
Predecessor [Member] | Warrant [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants to purchase common shares																									175,789	400,000	878,947	351,578
Warrant exercise price																										$ 2.30	$ 1
Exercise term																											5 years
Fair value of warrants																									$ 153,324		$ 766,384
Predecessor [Member] | Common Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Conversion of shares converted																	6,406,210
Predecessor [Member] | 2014 Equity Incentive Plan [Member]
Subsidiary, Sale of Stock [Line Items]
Common stock share increase																														0
Successor [Member] | Common Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Conversion of shares converted																	36,340
[1]Warrants represent the reset of the exercise price of the PIPE Warrants to purchase 24,672 70.00 966,349 208,702

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)					1 Months Ended	2 Months Ended	11 Months Ended	12 Months Ended
	Jan. 30, 2024	Jan. 02, 2024	Jan. 01, 2024	Feb. 28, 2023	Dec. 31, 2022	Mar. 15, 2024	Dec. 12, 2022	Dec. 31, 2023	Feb. 23, 2024
Subsequent Event [Line Items]
Gross proceeds pre-funded warrants								$ 1,126
Subsequent Event [Member] | 2022 Omnibus Equity Incentive Plan [Member]
Subsequent Event [Line Items]
Number of shares increased			317,891
Subsequent Event [Member] | December 2023 Offering [Member]
Subsequent Event [Line Items]
Warrants to purchase common shares						2,138,000			1,314,806
Warrant exercise price						$ 1.25			$ 0.0001
Gross proceeds pre-funded warrants						$ 2,672,500
Warrants exercised on cashless basic									1,315,000
License Agreement [Member] | L&F Research LLC [Member] | Waiver B [Member]
Subsequent Event [Line Items]
Cash payment				$ 500,000
License Agreement [Member] | L&F Research LLC [Member] | Waiver B [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Cash payment	$ 500,000
Marketing Agreement [Member] | Vendor [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Issued for services, shares		90,000
Prepaid expenses		$ 79,200